[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1561
1. Horn LC, Trost M, Bilek K: Staging of endometrial carcinoma: aspects of ovarian and cervical involvement. Int J Gynecol Pathol; 2010 Jan;29(1):63-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of endometrial carcinoma: aspects of ovarian and cervical involvement.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Gynecol Pathol. 2009 Jan;28(1):1-9 [19047915.001]
  • (PMID = 19952935.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


2. Chura JC, Brooker D, Downs LS Jr: Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature. Gynecol Oncol; 2006 Oct;103(1):336-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature.
  • BACKGROUND: Carcinoma of the urinary bladder that occurs after urinary diversion is a rare entity.
  • We report a case of an adenocarcinoma arising in a defunctionalized bladder that presented as locally advanced endometrial carcinoma.
  • The patient underwent anterior pelvic exenteration for a locally advanced mucinous carcinoma thought to be arising from the uterus and invading into the bladder.
  • Final pathology, however, was consistent with a primary bladder carcinoma.
  • CONCLUSION: Carcinoma developing in the bladder after urinary diversion presents at an advanced stage and has associated poor overall survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Urinary Diversion / adverse effects

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793125.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Soto-Cruz I, Rangel-Corona R, Valle-Mendiola A, Moreno-Morales X, Santiago-Pérez R, Weiss-Steider B, Cáceres-Cortés JR: The tyrphostin B42 inhibits cell proliferation and HER-2 autophosphorylation in cervical carcinoma cell lines. Cancer Invest; 2008 Mar;26(2):136-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tyrphostin B42 inhibits cell proliferation and HER-2 autophosphorylation in cervical carcinoma cell lines.
  • Constitutive phosphorylation of HER-2 protein has been implicated in conferring uncontrolled growth to mammary cancer cells, and to a lesser extent, with adenocarcinoma of uterus, cervix, fallopian tube, and endometrium.
  • This study addresses the role of HER-2 in cervical carcinoma.
  • Firstly, we demonstrate the presence of HER-2 protein expression by flow cytometry in two new cervical carcinoma cell lines CALO and INBL.
  • The most efficient agent, Tyrphostin B42, known as an inhibitor of epithelial growth factor receptor, arrested cervical carcinoma cell lines growth in vitro at micromolar concentrations within 72 h of application.
  • Thus, the inhibition of the proliferation of our cervical carcinoma cell lines by Tyrphostin B42 is associated with inhibition of HER2 protein kinase signal.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Receptor, ErbB-2 / metabolism. Tyrphostins / pharmacology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


Advertisement
4. Temkin SM, Pezzullo JC, Hellmann M, Lee YC, Abulafia O: Is body mass index an independent risk factor of survival among patients with endometrial cancer? Am J Clin Oncol; 2007 Feb;30(1):8-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is body mass index an independent risk factor of survival among patients with endometrial cancer?
  • OBJECTIVE: To evaluate whether body mass index (BMI) is an independent risk factor for survival in patients with endometrial adenocarcinoma.
  • METHODS: Women treated for endometrial cancer at the State University of New York (SUNY), Downstate and Kings County Hospital between January 1982 and September 2003 were eligible.
  • Patients were divided into groups based upon their histology at the time of diagnosis.
  • The first included patients with low-grade endometrioid adenocarcinoma (FIGO grades 1 and 2); the second included grade 3 endometrioid adenocarcinoma; and the third contained papillary serous and clear cell carcinomas.
  • There were 312 patients (70%) treated for low-grade endometrial adenocarcinoma; 64 patients (14%) for grade 3 endometrioid adenocarcinoma; and 71 patients (16%) for papillary serous and clear cell adenocarcinoma.
  • BMI was also correlated to tumor grade, stage at diagnosis, age, and race.
  • Statistical analyses revealed the majority of the association between BMI and survival can be attributed to the association between BMI and these other risk factors for survival in endometrial cancer.
  • CONCLUSIONS: Increased BMI is associated with survival advantage among patients with endometrial cancer.
  • [MeSH-major] Adenocarcinoma / physiopathology. Body Mass Index. Endometrial Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278888.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Wang XY, Pan ZM, Xie X: [Accuracy of preoperative tumor grading and intraoperative gross examination of myometrial invasion in clinical stage I endometriod adenocarcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2009 Jul;44(7):518-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Accuracy of preoperative tumor grading and intraoperative gross examination of myometrial invasion in clinical stage I endometriod adenocarcinoma].
  • OBJECTIVE: To evaluate accuracy of preoperative tumor grade and intraoperative gross examination of myometrial invasion in patients with clinical stage I endometriod adenocarcinoma for lymphadenectomy.
  • METHODS: Clinic-pathological data were retrospectively collected from 687 patients with clinical stage I endometriod adenocarcinoma who underwent operation in Women's Hospital, Zhejiang University School of Medicine from January 1999 to December 2008.
  • According to postoperative histology diagnosis, accuracy of preoperative tumor grade by curettage and depth of myometrial invasion by intraoperative gross examination was evaluated, and clinic-pathological factors associated with accuracy were analyzed.
  • RESULTS: Sensitivity, specificity, accuracy, false negative rate, false positive rate, and positive and negative predictive value for the prediction of needing for intraoperative lymphadenectomy in patients with clinical stage I endometriod adenocarcinoma were 70.4%, 80.2%, 77.6%, 12.0%, 43.0%, 57.0% and 88.0%, respectively.
  • CONCLUSION: Prediction of needing for lymphadenectomy by preoperative tumor grade and intraoperative gross examination of myometrial invasion is reliable in clinical stage I endometriod adenocarcinoma patients, while there is a highly false negative rate in prediction of not needing for lymphadenectomy, while other prognostic factors such as patient age, tumor size, lymph node metastasis and extrauterine spread lesion should be together considered.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Curettage / methods. Endometrial Neoplasms / pathology. Myometrium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957552.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Kommoss S, Rochon J, Harter P, Heitz F, Grabowski JP, Ewald-Riegler N, Haberstroh M, Neunhoeffer T, Barinoff J, Gomez R, Traut A, du Bois A: Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol; 2010 Jan;17(1):279-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer.
  • BACKGROUND: Treatment of advanced-stage ovarian carcinoma includes radical cytoreductive surgery, which aims at removing all visible tumor tissue followed by platinum and paclitaxel chemotherapy.
  • This paper reports on the prognostic impact of extensive surgery and surgical morbidity in patients with advanced-stage ovarian carcinoma.
  • METHODS: Patients with ovarian carcinoma [Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage IIIB-IV] undergoing primary surgery in our tertiary gynecologic oncology unit between 1997 and 2007 were eligible for this study.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898901.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Steffensen KD, Waldstrøm M, Jakobsen A: The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer; 2009 Jul;19(5):820-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
  • OBJECTIVE: Although platinum-based chemotherapy remains the cornerstone for treatment of ovarian cancer, some patients are resistant to the treatment and will therefore not benefit from the standard platinum-based chemotherapy.
  • The primary aim of the present study was to investigate if immunohistochemical expression of ERCC1 protein was associated with resistance to standard combination carboplatin and paclitaxel chemotherapy in newly diagnosed ovarian cancer patients.
  • METHODS: Formalin-fixed, paraffin-embedded tissue sections from 101 patients with newly diagnosed ovarian cancer were used for immunohistochemical staining for the ERCC1 protein.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Aged. Carboplatin / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Immunoenzyme Techniques. Middle Aged. Paclitaxel / administration & dosage. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574766.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; BG3F62OND5 / Carboplatin; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Dede M, Gezginç K, Ulubay M, Alanbay I, Güran S, Yenen M: A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer. Eur J Gynaecol Oncol; 2008;29(2):200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer.
  • As is known, tamoxifen therapy is related to endometrial proliferation, hyperplasia, polyp formation, invasive carcinoma and uterine sarcoma.
  • Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Aged. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Female. Humans. Middle Aged. Stomach Neoplasms / chemically induced. Uterine Cervical Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459568.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


9. Humber C, Tierney J, Symonds P, Collingwood M, Kirwan J, Williams C, Green J: Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev; 2005;(4):CD003915
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
  • BACKGROUND: Endometrial adenocarcinoma is a common gynaecological cancer, but a comparatively small proportion of patients present with or develop recurrent or advanced disease.
  • OBJECTIVES: To assess any benefits or adverse effects of cytotoxic chemotherapy in women with advanced, recurrent or metastatic endometrial adenocarcinoma.
  • Only one trial showed a significant survival benefit from the addition of paclitaxel to combination chemotherapy, but this was at the expense of increased toxicity.
  • AUTHORS' CONCLUSIONS: The optimum cytotoxic drug regimen for advanced endometrial adenocarcinoma has still to be defined although our review suggests that it may contain paclitaxel or platinum.
  • These mainly North American and European trial populations represent a highly selected subgroup of the 10,000 women dying annually from this disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2012;8:CD003915 [22895938.001]
  • [UpdateOf] Cochrane Database Syst Rev. 2005;(3):CD003915 [16034916.001]
  • (PMID = 16235346.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 109
  •  go-up   go-down


10. Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, Braun J, Soslow RA: Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer; 2006 Jul 1;107(1):90-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome.
  • BACKGROUND: Epithelial membrane protein 2 (EMP2) is an estrus-regulated tetraspan protein that is required for endometrial competence in blastocyst implantation.
  • These features suggest that EMP2 may contribute to neoplastic traits of endometrial cancer.
  • The objective of this study was to determine the prevalence of EMP2 expression in endometrial neoplasms and its clinical significance.
  • METHODS: EMP2 immunophenotype, histologic diagnosis, grade, the presence of lymphovascular invasion, disease stage, and clinical follow-up were determined for 99 endometrial cancers.
  • RESULTS: Significant EMP2 expression (EMP2 positive) was observed in 12 of 99 cancers (9 endometrioid [6 International Federation of Gynecology and Obstetrics Grade 3], 1 serous, 1 mixed endometrioid and serous, and 1 mixed endometrioid and clear cell), and weak EMP2 expression was observed in 11 cancers.
  • CONCLUSIONS: EMP2 expression is a feature of some prognostically unfavorable endometrial cancers.
  • Its utility for clinical decision making and its biologic role in endometrial cancer deserves further study in a larger series of patients.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16736513.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16042-29; United States / NCI NIH HHS / CA / CA016042; United States / NICHD NIH HHS / HD / HD048540; United States / NCATS NIH HHS / TR / UL1 TR000124; United States / NICHD NIH HHS / HD / HD40376; United States / NCI NIH HHS / CA / T32 CA009120
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EMP2 protein, human; 0 / Membrane Glycoproteins
  •  go-up   go-down


11. Watanabe Y, Kitagawa R, Aoki D, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N, Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group: Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group. Gynecol Oncol; 2009 Dec;115(3):456-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group.
  • OBJECTIVE: To determine the current status of postoperative management of endometrial cancer in Japan by surveying members of the Japanese Gynecologic Oncology Group (JGOG).
  • A total of 4063 patients with endometrial cancer were treated at the member institutions of the JGOG over a year.
  • Furthermore, more than 50% of respondent institutions performed adjuvant therapy when patients exhibited International Federation of Gynecology and Obstetrics (FIGO) stage IB/G3/positive lymph-vascular space invasion (LVSI)/endometrioid adenocarcinoma or FIGO IB/G3/non-endometrioid histology, and more than 90% institutions administered adjuvant therapy when patients exhibited FIGO IC/G3/positive LVSI/endometrioid adenocarcinoma or FIGO stage IC/G3/regardless of LVSI/non-endometrioid histology.
  • CONCLUSION: The present survey provides relevant information regarding the current status of adjuvant therapy in Japanese patients with endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / surgery. Practice Patterns, Physicians'

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19765806.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Kurvinen K, Rantanen V, Syrjänen S, Johansson B: Radiation-induced effects on telomerase in gynecological cancer cell lines with different radiosensitivity and repair capacity. Int J Radiat Biol; 2006 Dec;82(12):859-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced effects on telomerase in gynecological cancer cell lines with different radiosensitivity and repair capacity.
  • Thus, we have investigated radiation-induced effects on telomerase in six gynecological cancer cell lines, with different intrinsic radiosensitivity and capacity for sublethal damage repair (SLDR).
  • MATERIALS AND METHODS: Three endometrial adenocarcinoma (UM-EC-1, UT-EC-2B and UT-EC-3) and three vulvar squamous cell carcinoma (A431, UM-SCV-2 and UM-SCV-7) cell lines were irradiated with doses of 5, 10 and 25 Gy and the effects on telomerase were evaluated at 0.5, 6, 24 and 48 h post-irradiation.
  • In contrast to that, telomerase activities in the highly radiosensitive cell line UT-EC-2B remained below the basal level throughout the 48-h period of post-irradiation with the highest doses, and even a decline to approximately 50% of the basal level was found 24 h after exposure.

  • Genetic Alliance. consumer health - Radiation induced cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178626.001).
  • [ISSN] 0955-3002
  • [Journal-full-title] International journal of radiation biology
  • [ISO-abbreviation] Int. J. Radiat. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


13. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • We report on a very rare case of peritoneal clear cell adenocarcinomas.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • Two peritoneal cystic tumors were detected by imaging modalities around the stomach and spleen, 15 months and 21 months after the follow-up period of the endometrial carcinoma, respectively.
  • They showed proliferation of carcinoma cells arranged in solid nest, tubular, and papillary patterns.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • The morphologies and immunohistochemical findings of the two peritoneal clear cell adenocarcinomas were different from those of endometrial carcinoma.
  • We believe that the two clear cell adenocarcinomas are not metastatic lesions from the endometrial carcinoma of the uterus, and that they are primary clear cell adenocarcinomas of the peritoneum.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Allison KH, Reed SD, Voigt LF, Jordan CD, Newton KM, Garcia RL: Diagnosing endometrial hyperplasia: why is it so difficult to agree? Am J Surg Pathol; 2008 May;32(5):691-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosing endometrial hyperplasia: why is it so difficult to agree?
  • Current World Health Organization classification of endometrial hyperplasia is problematic because of poor diagnostic reproducibility.
  • We sought to determine factors that cause diagnostic disagreement in a review of 2601 endometrial specimens.
  • Blinded random specimens of normal endometrium, hyperplasias, and carcinoma were reviewed by 2 pathologists, with review by a third pathologist in cases with disagreement.
  • All cases of endometrial hyperplasia or carcinoma were scored for degree of glandular crowding, architectural complexity, and cytologic atypia.
  • Sample adequacy, hyperplasia volume, presence of metaplasia, or endometrial polyp were also scored.
  • The percent specific agreement was 90.3% for no hyperplasia, 31.1% for simple hyperplasia, 51.1% for complex hyperplasia, 49.8% for atypical hyperplasia, and 57.5% for adenocarcinoma.
  • Architectural crowding, architectural complexity, or the presence of a polyp were all associated with diagnostic disagreement (P<0.0001).
  • High diagnostic disagreement in endometrial hyperplasia is related to both sample adequacy and interpretation of histologic features present.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Hyperplasia / diagnosis. Endometrial Neoplasms / diagnosis. Endometrium / pathology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Diagnosis, Differential. Female. Humans. Middle Aged. Observer Variation. Reproducibility of Results. Single-Blind Method. World Health Organization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):103-14 [17413975.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):301-9 [11109157.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4311-4 [11389050.001]
  • [Cites] Int J Gynecol Cancer. 2004 Mar-Apr;14(2):348-53 [15086736.001]
  • [Cites] Am J Obstet Gynecol. 1966 Jan 1;94(1):134-55 [5321298.001]
  • [Cites] Pathol Annu. 1972;7:201-29 [4557932.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Am J Clin Pathol. 1978 Nov;70(5):770-9 [717282.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):403-12 [4005805.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):33-7 [8986530.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):1012-9 [9706982.001]
  • [Cites] Int J Gynaecol Obstet. 1999 Jun;65(3):243-9 [10428343.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1102-8 [10478671.001]
  • [Cites] J Obstet Gynaecol Br Commonw. 1961 Aug;68:668-72 [13690268.001]
  • [Cites] Am J Obstet Gynecol. 1963 Jun 15;86:433-43 [13967897.001]
  • [Cites] Am J Obstet Gynecol. 1963 Nov 1;87:662-78 [14074031.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):324-30 [15529181.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):812-9 [16400639.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):804-11 [16400640.001]
  • [Cites] J Pathol. 2000 Mar;190(4):462-9 [10699996.001]
  • (PMID = 18347507.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD044813; United States / NICHD NIH HHS / HD / R01 HD044813-04
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS103495; NLM/ PMC2682169
  •  go-up   go-down


15. Childs AJ, Burke JJ 2nd, Perry MY, Gallup DG: Metastatic uterine serous carcinoma originating in an endometrial polyp: a report of 2 cases. J Reprod Med; 2005 Mar;50(3):209-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic uterine serous carcinoma originating in an endometrial polyp: a report of 2 cases.
  • BACKGROUND: Endometrial carcinoma is the most common cancer of the female genital tract.
  • Two histologic variants have been described: an estrogen-dependent form and a more aggressive, non-estrogen-dependent form, which includes uterine serous carcinoma.
  • CASES: Two cases of uterine serous carcinoma were confined to an endometrial polyp without myometrial invasion and were widely metastatic.
  • Both patients had elevated CA-125 levels.
  • Pathology showed metastatic disease originating in a small focus of serous adenocarcinoma at the tip of an endometrial polyp.
  • CONCLUSION: These cases emphasize the aggressive nature of uterine serous carcinoma despite insignificant myometrial invasion.
  • [MeSH-major] Cystadenocarcinoma, Serous / etiology. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Polyps / pathology. Uterine Neoplasms / etiology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841935.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Giordano G, D'Adda T, Gnetti L, Merisio C, Melpignano M: Endometrial mucinous microglandular adenocarcinoma: morphologic, immunohistochemical features, and emphasis in the human papillomavirus status. Int J Gynecol Pathol; 2006 Jan;25(1):77-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial mucinous microglandular adenocarcinoma: morphologic, immunohistochemical features, and emphasis in the human papillomavirus status.
  • We report two cases of endometrial microglandular adenocarcinoma, a rare neoplasm, which, in its morphologic features, mimics cervical microglandular hyperplasia and mucinous proliferations of endometrium.
  • The criteria for a correct pathological diagnosis, such as clinical, morphologic, and immunohistochemical data, are emphasized.
  • For the first time, we probed to establish whether endometrial mucinous microglandular adenocarcinoma could be correlated to human papilloma virus (HPV) infection by using polymerase chain reaction amplification (PCR) of tumoral DNA.
  • Similar to previous studies reported in the literature, the present lesions, occurring in postmenopausal women, immunohistochemically showed positivity for B72.3, Ca 125, CEA, Vimentin, estrogen and progesterone receptors, and negativity for p53.
  • Molecular study by PCR amplification of tumor DNA showed no signal for HPV DNA in any of these cases; thus, this variant of endometrial carcinoma is not caused by the HPV infection, but probably by other pathogenetic mechanisms, such as an accumulation of the mutations, which arrive in old age or as the consequence of a peculiar hormonal situation.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Endometrial Neoplasms / pathology. Papillomaviridae / isolation & purification. Papillomavirus Infections / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. DNA, Neoplasm / analysis. DNA, Viral / analysis. Diagnosis, Differential. Endometrial Hyperplasia / diagnosis. Female. Humans. Hysterectomy. Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16306789.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / DNA, Viral
  •  go-up   go-down


17. Rubatt JM, Slomovitz BM, Burke TW, Broaddus RR: Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. Gynecol Oncol; 2005 Nov;99(2):472-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
  • BACKGROUND: Conservative treatment with progestins is a reasonable treatment option for endometrial complex atypical hyperplasia and, in the experimental setting, for some women with grade 1 endometrial endometrioid adenocarcinoma.
  • The risk of progression to a high-stage endometrial cancer is quite low, with only two previously reported cases in the English literature.
  • CASE: A 40-year-old woman with endometrial complex atypical hyperplasia diagnosed by dilatation and curettage was managed conservatively with progestin therapy (initially, megesterol acetate; then, a combination oral contraceptive).
  • More than 2 years after her original diagnosis, she developed endometrial endometrioid adenocarcinoma, FIGO grade 2, with lymph node metastasis.
  • CONCLUSION: Currently, there are no good criteria for predicting which patients with complex atypical hyperplasia/grade 1 endometrioid adenocarcinoma will optimally respond to progestin therapy.
  • There is some evidence that endometrial complex hyperplasia demonstrating loss of MLH1 protein by immunohistochemistry is strongly related to subsequent or concurrent endometrial cancer, especially tumors of higher grade and stage.
  • In a woman with a biopsy diagnosis of endometrial hyperplasia, evaluation of MLH1 protein status by immunohistochemistry may provide useful information when medical management is being considered.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / drug therapy. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Progestins / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099019.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCI NIH HHS / CN / N01-CN-05127
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Progestins
  •  go-up   go-down


18. Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, Ruan A, Chao KC, Han CP: Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med; 2009;7:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study.
  • BACKGROUND: Endocervical adenocarcinomas (ECAs) and endometrial adenocarcinomas (EMAs) are malignancies that affect uterus; however, their biological behaviors are quite different.
  • [MeSH-major] Adenocarcinoma / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Endometrial Neoplasms / metabolism. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Biopsy. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Protein Array Analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2001 May;67(1):61-70 [11518467.001]
  • [Cites] Arch Gynecol Obstet. 2009 Sep;280(3):405-13 [19153755.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):4-10 [11781516.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Radiology. 2002 May;223(2):410-6 [11997546.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):217-23 [12068166.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Virchows Arch. 2003 Mar;442(3):271-7 [12647218.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] J Histochem Cytochem. 2003 Oct;51(10):1291-7 [14500697.001]
  • [Cites] Curr Treat Options Oncol. 2004 Apr;5(2):119-27 [14990206.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Pathol Res Pract. 1993 Sep;189(8):862-6 [8302707.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):41-7 [7817943.001]
  • [Cites] Nat Genet. 1995 May;10(1):114-6 [7647780.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):61-5 [9495360.001]
  • [Cites] Virchows Arch. 1999 Jan;434(1):23-8 [10071231.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):52-68 [15613856.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1497-504 [16224217.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):1026-30 [16831029.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1091-100 [16648864.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1310-6 [16799478.001]
  • [Cites] Clinics (Sao Paulo). 2006 Oct;61(5):417-24 [17072439.001]
  • [Cites] Actas Urol Esp. 2006 Sep;30(8):754-62 [17078572.001]
  • [Cites] Ann Surg Oncol. 2006 Dec;13(12):1633-44 [17013685.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):306-13 [17242700.001]
  • [Cites] J Negat Results Biomed. 2007;6:6 [17459164.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10686-93 [18006810.001]
  • [Cites] J Transl Med. 2007;5:54 [17971233.001]
  • [Cites] Arch Pathol Lab Med. 2008 Mar;132(3):402-23 [18318583.001]
  • [Cites] J Transl Med. 2008;6:31 [18559092.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:25 [18673574.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):1-3 [11781515.001]
  • (PMID = 19366452.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16
  • [Other-IDs] NLM/ PMC2672079
  •  go-up   go-down


19. Rieck GC, Freites ON, Williams S: Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. J Obstet Gynaecol; 2005 Jan;25(1):39-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer.
  • Tamoxifen therapy is associated with an increased risk of endometrial cancer.
  • There is controversy regarding the incidence of high-grade endometrial malignancies associated with tamoxifen therapy.
  • This retrospective study assesses pathological features of endometrial malignancy in patients with and without a history of tamoxifen therapy.
  • One hundred and ninety six women with endometrial cancer were identified.
  • 20 patients had a history of breast cancer being treated with adjuvant tamoxifen therapy and developed subsequently endometrial cancer.
  • The histology in women who had not taken tamoxifen showed: adenocarcinoma (97.1%), 1.7% had mixed mullerian tumour.
  • Women in the tamoxifen-treated group had: adenocarcinoma (85%), sarcoma (5%), mixed mullerian tumour (5%).
  • In this study the tamoxifen-treated group of patients developed endometrial malignancies with a higher incidence of poor prognostic malignancies (p = 0.01).
  • [MeSH-major] Endometrial Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / epidemiology. Adult. Aged. Aged, 80 and over. Breast Neoplasms / drug therapy. Chemotherapy, Adjuvant. Female. Hospitals, General. Humans. Middle Aged. Mixed Tumor, Mullerian / chemically induced. Mixed Tumor, Mullerian / epidemiology. Prognosis. Retrospective Studies. Risk Factors. Sarcoma / chemically induced. Sarcoma / epidemiology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16147692.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


20. Hadler-Olsen E, Wetting HL, Rikardsen O, Steigen SE, Kanapathippillai P, Grénman R, Winberg JO, Svineng G, Uhlin-Hansen L: Stromal impact on tumor growth and lymphangiogenesis in human carcinoma xenografts. Virchows Arch; 2010 Dec;457(6):677-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal impact on tumor growth and lymphangiogenesis in human carcinoma xenografts.
  • Squamous cell carcinomas (SCCs) arising in the oral cavity are associated with poor survival, mainly due to metastatic disease.
  • To study influence of tongue and skin stroma on cancer growth and induction of lymphangiogenesis, xenograft tumors of human carcinoma cells were established either in tongue or skin of BALB/c nude mice.
  • Two oral and two skin SCC cell lines were used, as well as an endometrial adenocarcinoma cell line.
  • Our results show that the tumor stroma has a profound impact on cancer growth and induction of lymphangiogenesis and angiogenesis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Proliferation. Lymphangiogenesis. Skin Neoplasms / pathology. Tongue Neoplasms / pathology. Transplantation, Heterologous / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2004 Nov;445(5):456-64 [15375658.001]
  • [Cites] Histopathology. 2005 Aug;47(2):186-94 [16045780.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1232-42 [15803182.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7344-53 [16243806.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8364-71 [16322297.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4184-90 [16141354.001]
  • [Cites] Lymphology. 2005 Sep;38(3):107-10 [16353487.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2650-7 [16510584.001]
  • [Cites] J Pathol. 2006 May;209(1):67-77 [16482496.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):9-34 [16680569.001]
  • [Cites] Cancer Metastasis Rev. 2006 Jun;25(2):221-32 [16770534.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1779-87 [16931911.001]
  • [Cites] Immunol Rev. 2007 Jun;217:155-67 [17498058.001]
  • [Cites] Trends Immunol. 2007 Aug;28(8):340-5 [17627888.001]
  • [Cites] Adv Immunol. 2007;95:167-255 [17869614.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):554-6 [18538738.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):618-31 [18633355.001]
  • [Cites] Mutat Res. 2008 Jul-Aug;659(1-2):15-30 [18485806.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]
  • [Cites] J Oral Pathol Med. 2008 Nov;37(10):616-25 [19012622.001]
  • [Cites] PLoS One. 2008;3(11):e3812 [19043576.001]
  • [Cites] Circulation. 2009 Jan 20;119(2):281-9 [19118255.001]
  • [Cites] Ann Surg Oncol. 2009 Feb;16(2):233-9 [18825461.001]
  • [Cites] Am J Otolaryngol. 2009 Mar-Apr;30(2):121-33 [19239954.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):177-83 [19259624.001]
  • [Cites] Mol Oncol. 2008 Jun;2(1):41-53 [19383328.001]
  • [Cites] J Cell Biochem. 2009 Aug 15;107(6):1053-62 [19479945.001]
  • [Cites] J Histochem Cytochem. 2010 Jan;58(1):29-39 [19755718.001]
  • [Cites] Eur J Cancer. 2011 Jan;47(2):305-15 [20932741.001]
  • [Cites] J Biol Chem. 1999 Nov 5;274(45):32127-36 [10542248.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2821-8 [10914730.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1223-31 [11250889.001]
  • [Cites] EMBO J. 2001 Sep 3;20(17):4762-73 [11532940.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):293-8 [11801572.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1315-20 [11888898.001]
  • [Cites] Head Neck. 2002 Feb;24(2):165-80 [11891947.001]
  • [Cites] J Cell Physiol. 2002 Sep;192(3):259-67 [12124771.001]
  • [Cites] Int J Oncol. 2002 Dec;21(6):1317-23 [12429983.001]
  • [Cites] Blood. 2003 Jan 1;101(1):168-72 [12393704.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] APMIS. 2003 Nov;111(11):1011-8 [14629267.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jan;33(1):2-7 [14690652.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):74-80 [14634646.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 May;118(5):542-7 [1571132.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3566-70 [7724599.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):290-98 [8617204.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Science. 1997 May 30;276(5317):1423-5 [9162011.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3898-911 [9233800.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):548-53 [9435229.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):385-94 [10027397.001]
  • [Cites] J Cell Biol. 1999 Feb 22;144(4):789-801 [10037799.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(3):279-84 [10352881.001]
  • (PMID = 20890764.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Serum Amyloid P-Component; 0 / Vascular Endothelial Growth Factor C
  • [Other-IDs] NLM/ PMC2995317
  •  go-up   go-down


21. Smith SM, Hoffman MS: The role of vaginal hysterectomy in the treatment of endometrial cancer. Am J Obstet Gynecol; 2007 Aug;197(2):202.e1-6; discussion 202.e6-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of vaginal hysterectomy in the treatment of endometrial cancer.
  • OBJECTIVE: The objective of the study was to evaluate the role of vaginal hysterectomy in the treatment of endometrial cancer.
  • STUDY DESIGN: Medical records were retrospectively reviewed for patients undergoing vaginal hysterectomy for endometrial cancer at the University of South Florida.
  • The medical data were reviewed for medical comorbidities, preoperative and postoperative diagnosis, hospital course, surgical and postoperative complications, adjuvant treatments, and follow-up.
  • RESULTS: Sixty-three women underwent vaginal hysterectomy for endometrial carcinoma between May 1987-September 2006.
  • Of patients with intrauterine pathology, 89.5% had endometrioid adenocarcinoma.
  • CONCLUSION: Vaginal hysterectomy may be appropriate treatment of endometrial carcinoma for select patients.
  • [MeSH-major] Endometrial Neoplasms / surgery. Hysterectomy, Vaginal

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2009 Feb;200(2):e13-4 [18722577.001]
  • (PMID = 17689651.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Cirpan T, Terek MC, Mgoyi L, Zekioglu O, Iscan O, Ozsaran A: Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium. Eur J Gynaecol Oncol; 2006;27(4):389-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium.
  • OBJECTIVE: The aim of this study was to reclassify endometrial hyperplasia cases and examine PTEN protein immunoreactivity compared to cases with endometrial adenocarcinoma and proliferative endometrium.
  • DESIGN: Endometrial samples from 37 women with endometrial hyperplasia with atypia were reclassified as endometrial intraepithelial neoplasia (EIN).
  • Eighteen were complex and 19 were simple endometrial hyperplasia.
  • Twenty-our cases of EIN, ten endometrial adenocarcinoma cases and ten proliferative phase endometrium sections were immunostained for PTEN expression.
  • RESULTS: Twenty-four of 37 (64%) women with endometrial hyperplasia were reclassified as EIN.
  • There were no difference in PTEN immunoreactivity between EIN, endometrial adenocarcinoma and endometrial proliferation (p = 0.342).
  • PTEN immunoreactivity was partially lost in seven and present in three of the patients with endometrial adenocarcinoma.
  • CONCLUSION: EIN classification may provide a better and more objective assessment of endometrial hyperplasia cases.
  • PTEN expression showed no differences among the cases of EIN, endometrial carcinoma and proliferative phase endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Proliferation. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. PTEN Phosphohydrolase / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009632.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


23. Pozharisskiĭ KM, Vinokurov VL, Zharinov GM, Bolbarian NA, Kuznetsova ME, Gasparian NA, Samsonova EA: [Immunohistochemical markers as prognosticators in gynecologic oncology]. Vopr Onkol; 2008;54(4):463-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclooxygenase and particularly COX-2 expression impaired survival in patients operated on for endometrial adenocarcinoma of the uterus: 5-year overall and relapse-free survival in absence of expression was 92% and 88%, respectively, while in cases of distinct expression, it fell down to 52% and 48%, respectively (p = 0.0004; 0.0005).
  • The end-results of radiotherapy were associated with proliferative levels of squamous cell cervical carcinoma: for Ki-67--below median of < or = 50%, 5-year survival rate was 77%, mean survival--80 months; for Ki-67 above median of > or = 50%, the indices were 47% and 47 months, respectively, (p = 0.002).
  • [MeSH-major] Biomarkers, Tumor / analysis. Genital Neoplasms, Female / chemistry. Genital Neoplasms, Female / diagnosis. Immunohistochemistry
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adult. Aged. Cyclooxygenase 1 / analysis. Cyclooxygenase 2 / analysis. Disease-Free Survival. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Female. Gene Expression Regulation, Developmental. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Tumor Suppressor Protein p53 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942401.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


24. Sato S, Itamochi H, Shimada M, Fujii S, Naniwa J, Uegaki K, Sato S, Nonaka M, Ogawa T, Kigawa J: Preoperative and intraoperative assessments of depth of myometrial invasion in endometrial cancer. Int J Gynecol Cancer; 2009 Jul;19(5):884-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative and intraoperative assessments of depth of myometrial invasion in endometrial cancer.
  • OBJECTIVE: Preoperative and intraoperative assessments of myometrial invasion (MI) are commonly used for planning surgical procedures such as dissection of the para-aortic node; however, the assessments often differ from the final diagnosis determined by pathological examination.
  • METHODS: A total of 191 patients with endometrial cancer, who underwent hysterectomy from 1995 to 2007 in Tottori University Hospital, were included in this study.
  • One hundred seventy-four patients underwent endometrial curettage or Pipelle biopsy preoperatively.
  • During surgery, the uterine wall was incised at the most invasive part, and then, intraoperative gross assessment was evaluated as less than or greater than 50%.
  • Regarding the diagnosis of greater than 50% MI depth, the accuracy, the sensitivity, and the specificity of the MRI assessment were 83.2%, 75.0%, and 85.7%, respectively.
  • [MeSH-major] Endometrial Neoplasms / pathology. Myometrium / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Female. Humans. Hysterectomy. Intraoperative Care. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Preoperative Care. Prognosis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574778.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Abu J, Brown L, Ireland D: Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (mirena) in a 36-year-old woman. Int J Gynecol Cancer; 2006 May-Jun;16(3):1445-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (mirena) in a 36-year-old woman.
  • It has a 32-mm long-shaped plastic frame that holds a reservoir (on the vertical stem) of 52 mg of levonorgestrel mixed with polydimethylsiloxane to allow a steady release of 20 mug of levonorgestrel per day within the endometrial cavity through a rate-limiting surface membrane.
  • This study included a 36-year old woman who developed endometrial cancer following the insertion of the LNG-IUS.
  • [MeSH-major] Carcinoma, Endometrioid / chemically induced. Endometrial Neoplasms / chemically induced. Intrauterine Devices, Medicated / adverse effects. Levonorgestrel / adverse effects

  • Hazardous Substances Data Bank. LEVONORGESTREL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803545.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; 5W7SIA7YZW / Levonorgestrel
  •  go-up   go-down


26. Augustin G, Kekez T, Bogdanic B: Abdominal papular zosteriform cutaneous metastases from endometrial adenocarcinoma. Int J Gynaecol Obstet; 2010 Jul;110(1):74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal papular zosteriform cutaneous metastases from endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20362987.001).
  • [ISSN] 1879-3479
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Pothuri B, Ramondetta L, Eifel P, Deavers MT, Wilton A, Alektiar K, Barakat R, Soslow RA: Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecol Oncol; 2006 Dec;103(3):948-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers.
  • INTRODUCTION: Previous reports have suggested that patients who have undergone pelvic radiation for cervical cancer are at risk for developing poorly differentiated endometrial cancers with poor prognoses.
  • MATERIALS AND METHODS: We conducted a retrospective chart and histologic review of patients from Memorial Sloan-Kettering Cancer Center and MD Anderson Cancer Center diagnosed with endometrial cancer after radiation therapy (RT) for cervical cancer from 1976 to 2000.
  • The comparison group comprised MSKCC endometrial cancer patients whose tumors were not radiation associated ("sporadic cancers").
  • RESULTS: We identified 23 patients who developed endometrial carcinoma or carcinomasarcoma after RT for cervical carcinoma and 527 sporadic endometrial cancer patients.
  • When radiation-associated endometrial cancers (RAECs) were compared with sporadic cancers, significant differences were noted with regard to stage, grade and histologic subtype distribution.
  • DISCUSSION: The clinicopathologic characteristics of RAECs, which include a preponderance of high-stage, high-grade and high-risk histologic subtypes, indicate that these tumors differ from sporadic endometrial carcinomas.
  • [MeSH-major] Endometrial Neoplasms / epidemiology. Neoplasms, Radiation-Induced / epidemiology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / etiology. Adenocarcinoma, Clear Cell / mortality. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / epidemiology. Carcinoma, Endometrioid / etiology. Carcinoma, Endometrioid / mortality. Carcinosarcoma / diagnosis. Carcinosarcoma / epidemiology. Carcinosarcoma / etiology. Carcinosarcoma / mortality. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / epidemiology. Cystadenocarcinoma, Serous / etiology. Cystadenocarcinoma, Serous / mortality. Female. Humans. Medical Records. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy / adverse effects. Retrospective Studies. Survival Analysis. Texas / epidemiology. Uterine Cervical Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16870239.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Salakos N, Bakalianou K, Deligeoroglou E, Kondi-Pafiti A, Papadias K, Creatsas G: Endometrial carcinoma presenting as hematometra: clinicopathological study of a rare case and literature review. Eur J Gynaecol Oncol; 2007;28(3):239-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma presenting as hematometra: clinicopathological study of a rare case and literature review.
  • A case of a postmenopausal woman who was investigated for a large cystic peritoneal tumor which turned out to be hematometra is presented.
  • From her clinical history, a wide excision of the uterine cervix was reported due to a high-grade intraepithelial squamous neoplasia.
  • Laparotomy showed a greatly enlarged uterus and the histological exam revealed a hematometra with a superficial endometrioid adenocarcinoma of the uterine cavity.
  • A review of the literature revealed that hematometra in postmenopausal women should be investigated because it may harbor a cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Postmenopause
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Hematometra / diagnosis. Humans. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624098.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


29. Largillier R, Valenza B, Ferrero JM, Novo C, Creisson A, Lesbats G, Mari V, Hebert C, Chamorey E: Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy. Oncology; 2007;73(3-4):177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
  • This retrospective cohort study included patients with ovarian cancer in relapse.
  • With the weekly strategy, an increase in dose density and a reduction in the number of delayed doses were observed.
  • This study suggests that the weekly administration of topotecan 4 mg/m(2), for 3 weeks out of every 4, results in a better maintenance of dose density and a reduction in haematological toxicity.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Aged. Aged, 80 and over. Cohort Studies. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Dose-Response Relationship, Drug. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / secondary. Female. Hematologic Diseases / chemically induced. Hematologic Diseases / prevention & control. Humans. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18418010.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


30. Sparr JA, Bandipalliam P, Redston MS, Syngal S: Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol; 2009 Feb;33(2):309-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a precancerous lesion with a well-described progression to carcinoma.
  • This case report describes a 61-year-old woman with a history significant for multiple cancers and a confirmed germline mutation of MSH2, a mismatch repair gene responsible for Lynch syndrome, who was also found to have an IPMN of the pancreas.
  • Phenotypic manifestations of Lynch syndrome in this patient included multiple adenomas and adenocarcinomas of the colon and also several other Lynch syndrome-associated cancers.
  • The patient's adenocarcinoma of the colon and IPMN of the pancreas showed identical immunohistochemical staining profiles with loss of expression of MSH2 and MSH6 proteins and high levels of microsatellite instability.
  • The immunohistochemical staining and microsatellite instability patterns of the adenocarcinoma of the colon and IPMN gives strong evidence to support the consideration of IPMN as part of the spectrum of lesions found in Lynch syndrome.

  • Genetic Alliance. consumer health - Lynch syndrome.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 1999 Nov;36(11):801-18 [10544223.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):444-9 [18398828.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3139-44 [11306499.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):537-42 [12808058.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):235-8 [14760534.001]
  • [Cites] Br J Cancer. 1985 Aug;52(2):271-3 [4027169.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1109-12 [1913482.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):677-85 [8431847.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1501-7 [9626054.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Arch Surg. 2006 Jan;141(1):51-6; discussion 56 [16415411.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1498-502 [16996571.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):803-13; discussion 813-4 [17481488.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • (PMID = 18987546.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA113433; United States / NCI NIH HHS / CA / K24 CA113433-04; United States / PHS HHS / / K24-113433
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ NIHMS77744; NLM/ PMC2631097
  •  go-up   go-down


31. Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A: Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol; 2008 Sep 10;26(26):4319-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
  • PURPOSE: Epidermal growth factor receptor (EGFR) overexpression is common in endometrial cancers and may have a major role in tumor growth and progression.
  • PATIENTS AND METHODS: A multinomial design two-stage phase II study was performed to evaluate single-agent activity of erlotinib in women with advanced endometrial cancer with recurrent or metastatic disease who were chemotherapy naïve and had received up to one line of prior hormonal therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use


32. Han CP, Lee MY, Kok LF, Wu TS, Cheng YW, Wang PH, Yue CH, Tyan YS: A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obstet; 2010 May;281(5):845-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
  • BACKGROUND: The choice of appropriate therapeutic plans for primary endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) depend on the tumor's site of origin.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Endometrial Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis


33. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N: Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet; 2010 Apr 3;375(9721):1165-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis.
  • BACKGROUND: In response to findings that pelvic lymphadenectomy does not have any therapeutic benefit for endometrial cancer, we aimed to establish whether complete, systematic lymphadenectomy, including the para-aortic lymph nodes, should be part of surgical therapy for patients at intermediate and high risk of recurrence.
  • METHODS: We selected 671 patients with endometrial carcinoma who had been treated with complete, systematic pelvic lymphadenectomy (n=325 patients) or combined pelvic and para-aortic lymphadenectomy (n=346) at two tertiary centres in Japan (January, 1986-June, 2004).
  • INTERPRETATION: Combined pelvic and para-aortic lymphadenectomy is recommended as treatment for patients with endometrial carcinoma of intermediate or high risk of recurrence.
  • FUNDING: Japanese Foundation for Multidisciplinary Treatment of Cancer, and the Japan Society for the Promotion of Science.
  • [MeSH-major] Endometrial Neoplasms / surgery. Lymph Node Excision
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aorta. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Hysterectomy. Kaplan-Meier Estimate. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Pelvis. Radiotherapy, Adjuvant. Survival Rate


34. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, Hrstka R, Janotova P, Radina M, Lane DP, Coates PJ, Vojtesek B: Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol; 2005 Nov;207(3):251-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutation and/or loss of the TP53 tumour suppressor gene is the single most common genetic abnormality in human cancer.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cyclin-Dependent Kinase Inhibitor p21 / genetics. DNA, Neoplasm / genetics. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Female. Humans. Immunohistochemistry / methods. Ki-67 Antigen / genetics. Mutation. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Phosphorylation. Transcription, Genetic / genetics. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16161005.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA, Neoplasm; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


35. Tay EH: Laparoscopic pelvic surgery for endometrial cancer. Ann Acad Med Singapore; 2009 Feb;38(2):130-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic pelvic surgery for endometrial cancer.
  • INTRODUCTION: The traditional approach for the treatment of endometrial cancer by laparotomy is increasingly being replaced by laparoscopic surgery.
  • Laparoscopy avoids the morbidity of a laparotomy, overcomes the limitations of vaginal hysterectomy, provides adequate pathological information for an accurate surgical staging and expedites the postoperative recovery of patients.
  • This paper reports the outcome of a series of 50 consecutive cases of laparoscopic hysterectomy and pelvic lymphadenectomy for endometrial cancers that were performed by the author.
  • The objective is to review the perioperative, postoperative experience and survival outcomes of patients with endometrial cancer managed by laparoscopic surgery performed by a single surgeon.
  • MATERIALS AND METHODS: The records of 50 consecutive patients with endometrial cancers from October 1995 to October 2007 treated by laparoscopic pelvic lymphadenectomy and laparoscopic hysterectomy (total and assisted) were retrospectively reviewed.
  • Data on patients' attributes, endometrial cancers, surgical procedures, surgical complications and morbidity, perioperative experience, length of hospital stays and clinical outcome were analysed.
  • RESULTS: Laparoscopic surgery was successful in all 50 patients and is clearly an option for the treatment of early endometrial cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / surgery. Hysterectomy / methods. Laparoscopy / methods

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19271040.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


36. Kalogiannidis I, Lambrechts S, Amant F, Neven P, Van Gorp T, Vergote I: Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome. Am J Obstet Gynecol; 2007 Mar;196(3):248.e1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome.
  • OBJECTIVE: To determine the feasibility of laparoscopic-assisted vaginal hysterectomy (LAVH) in the treatment of clinical FIGO stage I endometrial adenocarcinoma and long-term survival outcome.
  • Laparoscopy or laparotomy was selected based on size and mobility of the uterus and Body Mass Index (BMI).
  • LAVH was associated with more surgical FIGO stage IA disease and a smaller tumor diameter.
  • CONCLUSION: LAVH with lymphadenectomy in selected population in high-risk patients with clinical stage I endometrial adenocarcinoma and with favorable body mass index of less than 35 kg/m2, appears to be safe procedure.
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / surgery. Hysterectomy, Vaginal / methods. Laparoscopy


37. Kozawa E, Matsuo Y, Hasegawa K, Fujiwara K, Sakurai T, Kimura F: Spontaneously ruptured endometrioma associated with endometrioid adenocarcinoma: MR findings. Magn Reson Med Sci; 2010;9(4):233-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneously ruptured endometrioma associated with endometrioid adenocarcinoma: MR findings.
  • Magnetic resonance (MR) imaging revealed an irregular ovarian wall with a solid component and a fluid-fluid level in the cystic mass and the pelvic space, which was thought to be pathognomonic for the rupture of an endometrioma with a malignant ovarian tumor.
  • Histologic examination following adnexectomy revealed a ruptured endometrioma associated with endometrioid adenocarcinoma.
  • A fluid-fluid level in the cystic mass and pelvic space may be pathognomonic MRI feature for a rupture of either an endometrioma or an endometrioma with a malignant tumor.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Diagnosis, Differential. Female. Humans. Rupture, Spontaneous

  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187693.001).
  • [ISSN] 1880-2206
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Nikolov M, Dobrev N: [Rare cases of isolated metastatic process in the spleen from gynecological tumors]. Khirurgiia (Sofiia); 2007;(1-2):60-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Splenic Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18461038.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


39. Vilos GA, Ettler HC, Edris F, Hollett-Caines J, Abu-Rafea B: Endometrioid adenocarcinoma treated by hysteroscopic endomyometrial resection. J Minim Invasive Gynecol; 2007 Jan-Feb;14(1):119-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma treated by hysteroscopic endomyometrial resection.
  • A 53-year-old multiparous woman, with no identifiable risk factor for endometrial cancer, presented with menorrhagia.
  • Office endometrial biopsy indicated well-differentiated villoglandular adenocarcinoma of the endometrium.
  • We propose that skillful resectoscopic surgery, under specific circumstance, may be an appropriate alternative treatment to hysterectomy for some early uterine malignancies.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / surgery. Hysteroscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17218243.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Ohta Y, Hamatani S, Suzuki T, Ikeda K, Kiyokawa K, Shiokawa A, Kushima M, Ota H: Clear cell adenocarcinoma arising from a giant cystic adenomyosis: a case report with immunohistochemical analysis of laminin-5 gamma2 chain and p53 overexpression. Pathol Res Pract; 2008;204(9):677-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma arising from a giant cystic adenomyosis: a case report with immunohistochemical analysis of laminin-5 gamma2 chain and p53 overexpression.
  • We report a case of a clear cell adenocarcinoma arising from a giant cystic adenomyosis, with immunohistochemical analysis of p53 and laminin-5 gamma2 chain overexpression.
  • Microscopically, not only clear cell adenocarcinoma showing myometrial invasion but also single-layered clear cell adenocarcinoma cells lining the cyst wall were observed.
  • Although the tumor cells within the uterus showed a low positive cell ratio for p53, the metastatic foci showed a remarkable p53 overexpression.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology. Laminin / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467037.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LAMC2 protein, human; 0 / Laminin; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


41. Temkin SM, Hellman M, Lee YC, Abulafia O: Surgical resection of vulvar metastases of endometrial cancer: a presentation of two cases. J Low Genit Tract Dis; 2007 Apr;11(2):118-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of vulvar metastases of endometrial cancer: a presentation of two cases.
  • OBJECTIVE: Endometrial cancer generally carries a good prognosis.
  • Surgical resection of disease may be possible, therapeutic and even curative, in select patients with isolated cancer recurrence.
  • CASE 1: A 63-year-old patient presented 7 years after treatment of endometrial cancer with a vulvar lesion and groin mass.
  • The lesions were successfully resected and confirmed to be recurrent endometrial cancer.
  • However, she eventually died 8 months later because of a disease recurrence.
  • CASE 2: An 83-year-old patient with a history of a hysterectomy for endometrial cancer and radiation therapy for a vaginal vault recurrence presented with an exophytic labial mass.
  • After radical wide excision of her vulvar mass and bilateral groin dissection, final pathology revealed that the mass was consistent with recurrent endometrial cancer.
  • CONCLUSIONS: Uncommon sites of recurrence of endometrial cancer may include the vulva.
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / pathology. Gynecologic Surgical Procedures. Vulvar Neoplasms / surgery

  • Genetic Alliance. consumer health - Vulvar cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415118.001).
  • [ISSN] 1089-2591
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M, Sato A: Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol; 2008 Apr;109(1):122-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma.
  • OBJECTIVE: This study was conducted to determine whether tumor-associated macrophages (TAMs) correlate with clinicopathological features in endometrioid adenocarcinoma.
  • METHODS: 76 cases of endometrioid adenocarcinoma treated initially by hysterectomy with pelvic lymphadenectomy were retrospectively retrieved, and their histological features were evaluated.
  • TAMs may play a significant role in the biology of tumor progression of endometrial adenocarcinoma, but do not appear to be independent prognostic indicators of patient's survival.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Macrophages / pathology. Myometrium / pathology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289648.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


43. Horn LC, Hänel C, Bartholdt E, Dietel J: Serous carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature indicate the existence of 2 prognostically relevant tumor types. Int J Gynecol Pathol; 2006 Jul;25(3):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature indicate the existence of 2 prognostically relevant tumor types.
  • We report a serous carcinoma of the endometrium with a choriocarcinomatous component and review of the literature.
  • A 61-year-old woman underwent hysterectomy and bilateral salpingo-oophorectomy for a serous carcinoma with choriocarcinomatous component.
  • Despite chemotherapy, the patient died 2 months after initial diagnosis.
  • The second type presents as an endometrial carcinoma with single syncytiotrophoblast-like cells, associated with low serum hCG, no distant metastatic disease, and, consequently, a better prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Choriocarcinoma / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Cell Differentiation. Chorionic Gonadotropin / blood. Female. Humans. Middle Aged. Prognosis. Trophoblastic Neoplasms / blood. Trophoblastic Neoplasms / diagnosis. Trophoblastic Neoplasms / pathology. Trophoblasts / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810062.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  • [Number-of-references] 14
  •  go-up   go-down


44. Zhao JH, Wan XY, Xie X, Zhou CY, Wu QY: [Expression and clinical significance of Beclin1 and PTEN in endometrial carcinoma]. Ai Zheng; 2006 Jun;25(6):753-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of Beclin1 and PTEN in endometrial carcinoma].
  • BACKGROUND & OBJECTIVE: The pathogenesis of endometrial carcinoma is unclear.
  • This study was to explore the expression of beclin1 (BECN1) and PTEN in endometrial carcinoma, and investigate their correlations to clinicopathologic features of endometrial carcinoma.
  • METHODS: The expression of BECN1 and PTEN in 79 specimens of endometrial carcinoma, 34 specimens of endometrial hyperplasia, and 22 specimens of normal endometria were detected by PowerVision immunohistochemistry.
  • Their correlations to clinicopathologic features of endometrial carcinoma were analyzed.
  • RESULTS: The positive rates of BECN1 and PTEN were the highest in normal endometria, and diminished gradually in endometrial hyperplasia and endometrial carcinoma (93.33%, 58.82%, and 34.18%, Chi (2)=42.318, P<0.001, 93.33%, 64.71%, and 32.91%, Chi(2)=31.746, P<0.001).
  • The expression of BECN1 was positively correlated to that of PTEN in endometrial carcinoma.
  • CONCLUSION: The down-regulation of BECN1 and PTEN may be correlated to carcinogenesis of endometrioid adenocarcinoma.
  • [MeSH-major] Apoptosis Regulatory Proteins / metabolism. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Membrane Proteins / metabolism. PTEN Phosphohydrolase / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Down-Regulation. Endometrial Hyperplasia / metabolism. Endometrial Hyperplasia / pathology. Endometrium / metabolism. Endometrium / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764775.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BECN1 protein, human; 0 / Membrane Proteins; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


46. Alduaij A, Hansen K, Zhang C: Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report. Diagn Pathol; 2010;5:44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report.
  • We report a rare case of primary lymphoma of fallopian tube in a 68-year-old woman who underwent total hysterectomy and bilateral salpingo-oophorectomy for endometrial carcinoma.
  • The specimen showed a well-differentiated endometrioid adenocarcinoma with superficial myometrial invasion.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / pathology. Hysterectomy. Incidental Findings. Lymphoma, Follicular / pathology. Neoplasms, Multiple Primary. Ovariectomy

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):384-6 [12217767.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1933-43 [6627208.001]
  • [Cites] Int J Gynecol Pathol. 2006 Jan;25(1):1-21 [16306779.001]
  • [Cites] Int J Gynecol Pathol. 1991;10(4):394-401 [1774110.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):736-8 [15581994.001]
  • [Cites] Pathol Annu. 1991;26 Pt 1:227-63 [2014141.001]
  • (PMID = 20584306.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2905343
  •  go-up   go-down


47. Altundag O, Dursun P, Ayhan A: Emerging drugs in endometrial cancers. Expert Opin Emerg Drugs; 2010 Dec;15(4):557-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs in endometrial cancers.
  • IMPORTANCE OF THE FIELD: Endometrial cancer remains the most common gynecologic malignancy.
  • The treatment of endometrial cancer is rapidly evolving.
  • AREAS COVERED IN THIS REVIEW: In this article, we aim to review current and future treatment options in the medical treatment of endometrial cancers.
  • WHAT THE READER WILL GAIN: The cornerstone of curative therapy for patients with endometrial cancer is surgical treatment.
  • Cytotoxic chemotherapy is the mainstay of therapy for metastatic and advanced endometrial cancer.
  • Recent advances in the understanding of the molecular biology of endometrial cancer have led to development of targeted therapies.
  • TAKE HOME MESSAGE: Clinical trials are planned to further explore how to best incorporate novel agents into the current treatment algorithm with the aim to improve outcome for women with endometrial adenocarcinomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems. Endometrial Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Algorithms. Animals. Clinical Trials as Topic. Drug Design. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20828226.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


48. Wu HM, Lai CH, Huang HY, Wang HS, Soong YK: A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer. Chang Gung Med J; 2008 Jan-Feb;31(1):102-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer.
  • Endometrial cancer is predominately a postmenopausal disease.
  • Endometrial cancer in women of childbearing age is relatively unusual.
  • Endometrial cancer is typically treated with hysterectomy.
  • After the development of endometrial cancer, successful pregnancy is rare.
  • We present a case of recurrent stage I endometrial adenocarcinoma in a 35-year-old woman.
  • Magnetic resonance imaging (MRI) revealed endometrial lesions without myometrium invasion and no pelvic lymph node enlargement.
  • On the basis of these observations and the low malignant potential of well-differentiated endometrial carcinoma, fertility-preserving treatment using Megace therapy was suggested.
  • Recurrent endometrial adenocarcinoma was documented using hysteroscopy and direct endometrial biopsy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Endometrial Neoplasms / drug therapy. Fertilization in Vitro. Megestrol Acetate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Twins

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419059.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


49. Lin MC, Lomo L, Baak JP, Eng C, Ince TA, Crum CP, Mutter GL: Squamous morules are functionally inert elements of premalignant endometrial neoplasia. Mod Pathol; 2009 Feb;22(2):167-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous morules are functionally inert elements of premalignant endometrial neoplasia.
  • Squamous morules are a common component of premalignant glandular lesions that are followed by glandular, rather than squamous, carcinomas.
  • We tested the hypothesis that the appearance of glands associated with morules predicts cancer risk, and undertook molecular testing to determine the clonal and hormonal response properties of admixed squamous and glandular elements.
  • A total of 66 patients with squamous morules in an index endometrial biopsy had follow-up clinical data (average follow-up: interval 31 months, 2.5 biopsies) showing development of carcinoma in 11% (7/66) of cases.
  • The histological appearance of morule-associated glands in the index biopsy was significantly associated with this clinical outcome, with the majority (71%, 5/7) of cancer occurrences following an overtly premalignant lesion (endometrial intraepithelial neoplasia) with squamous morules.
  • Eight endometrial intraepithelial neoplasias with squamous morules were examined by immunohistochemistry for estrogen and progesterone receptors and mitotic activity (Ki-67 antigen percent stained).
  • The clinical and laboratory data are consistent with a model of morule biology in which squamous morules are a hormonally incompetent subpopulation of endometrial glandular lesions.
  • Subsequent cancer risk, as promoted by estrogens, is greatest when the glandular component has the appearance of endometrial intraepithelial neoplasia.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):103-14 [17413975.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1322-9 [16160475.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):924-30 [10841828.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):169-76 [11063639.001]
  • [Cites] J Pathol. 2001 May;194(1):59-67 [11329142.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4311-4 [11389050.001]
  • [Cites] Am J Obstet Gynecol. 2002 Apr;186(4):651-7 [11967486.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):326-31 [11986334.001]
  • [Cites] Gynecol Oncol. 2003 Feb;88(2):108-17 [12586588.001]
  • [Cites] Breast Cancer Res. 2003;5(2):63-8 [12631383.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):1008-13 [14984979.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer. 1986 Jan 15;57(2):340-5 [3942966.001]
  • [Cites] Semin Diagn Pathol. 1988 May;5(2):154-71 [3041509.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jul;14(3):230-4 [8600074.001]
  • [Cites] J Pathol. 1996 Nov;180(3):275-82 [8958805.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):320-7 [9010105.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3935-40 [9307275.001]
  • [Cites] J Pathol. 1997 Aug;182(4):429-36 [9306964.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4736-8 [9354433.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2500-3 [9635567.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):924-31 [9744308.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):324-30 [15529181.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2304-12 [15856484.001]
  • [Cites] J Pathol. 2000 Mar;190(4):462-9 [10699996.001]
  • (PMID = 19180120.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092301-02; United States / NCI NIH HHS / CA / R01 CA092301; United States / NCI NIH HHS / CA / R01 CA100833-01A1; United States / NCI NIH HHS / CA / R01 CA100833-05; United States / NCI NIH HHS / CA / R01-CA92301; United States / NCI NIH HHS / CA / R01 CA092301-01A1; United States / NCI NIH HHS / CA / R01 CA092301-02; United States / NCI NIH HHS / CA / R01 CA100833; United States / NCI NIH HHS / CA / R01 CA100833-03; United States / NCI NIH HHS / CA / R01 CA092301-03; United States / NCI NIH HHS / CA / CA100833-04; United States / NCI NIH HHS / CA / CA100833-03; United States / NCI NIH HHS / CA / R01 CA100833-02; United States / NCI NIH HHS / CA / CA092301-05; United States / NCI NIH HHS / CA / R01 CA092301-05; United States / NCI NIH HHS / CA / CA092301-03; United States / NCI NIH HHS / CA / R01 CA100833-04; United States / NCI NIH HHS / CA / CA100833-01A1; United States / NCI NIH HHS / CA / R01 CA092301-04; United States / NCI NIH HHS / CA / CA100833-05; United States / NCI NIH HHS / CA / CA092301-01A1; United States / NCI NIH HHS / CA / R01-CA100833; United States / NCI NIH HHS / CA / CA100833-02; United States / NCI NIH HHS / CA / CA092301-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ NIHMS71886; NLM/ PMC2633489
  •  go-up   go-down


50. Allhorn S, Böing C, Koch AA, Kimmig R, Gashaw I: TLR3 and TLR4 expression in healthy and diseased human endometrium. Reprod Biol Endocrinol; 2008;6:40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TLR3 and TLR4 expression in healthy and diseased human endometrium.
  • TLRs are expressed in the human endometrium and their regulation might be crucial for the pathogenesis of endometrial diseases.
  • METHODS: TLR3 and TLR4 expression was investigated during the menstrual cycle and in postmenopausal endometrium considering peritoneal endometriosis, hyperplasia, and endometrial adenocarcinoma specimens (grade 1 to 3).
  • In addition, TLR4 was present on endometrial dendritic cells, monocytes and macrophages.
  • In patients with peritoneal endometriosis, TLR3 and TLR4 mRNA expression decreased significantly in proliferative diseased endometrium compared to controls.
  • Endometrial hyperplasia and adenocarcinoma revealed significantly reduced receptor levels when compared with postmenopausal controls.
  • The lowest TLR expression levels were determined in poor differentiated carcinoma (grade 3).
  • CONCLUSION: Our data suggest an involvement of TLR3 and TLR4 in endometrial diseases as demonstrated by altered expression levels in endometriosis and endometrial cancer.
  • [MeSH-major] Endometrium / metabolism. Toll-Like Receptor 3 / biosynthesis. Toll-Like Receptor 4 / biosynthesis. Uterine Diseases / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adult. Aged. Endometrial Neoplasms / metabolism. Endometriosis / metabolism. Female. Gene Expression Regulation. Humans. Menstrual Cycle / physiology. Middle Aged. Postmenopause. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jan 15;164(2):966-72 [10623846.001]
  • [Cites] Placenta. 2000 Sep;21(7):733-41 [10985978.001]
  • [Cites] Crit Rev Immunol. 2001;21(1-3):179-89 [11642603.001]
  • [Cites] Cell Tissue Res. 2001 Nov;306(2):335-40 [11702245.001]
  • [Cites] Fertil Steril. 2001 Nov;76(5):1012-8 [11704126.001]
  • [Cites] J Immunol. 2002 Jan 15;168(2):554-61 [11777946.001]
  • [Cites] Gynecol Obstet Invest. 2002;53 Suppl 1:19-25 [11834864.001]
  • [Cites] Ann N Y Acad Sci. 2002 Mar;955:101-9; discussion 118, 396-406 [11949939.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1463-71 [12237915.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Annu Rev Immunol. 2003;21:335-76 [12524386.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):47-54 [14745724.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12542-50 [14729660.001]
  • [Cites] Am J Reprod Immunol. 2004 Jul;52(1):67-73 [15214945.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Jun;91(1-2):59-66 [15261308.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Dec 2;1:123 [14651748.001]
  • [Cites] Immunology. 2004 Oct;113(2):153-62 [15379975.001]
  • [Cites] Gynecol Obstet Invest. 2007;63(2):71-97 [17028437.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):905-12 [17324405.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1373-9 [17234676.001]
  • [Cites] J Reprod Immunol. 2007 Jun;74(1-2):53-60 [17292969.001]
  • [Cites] Immunol Lett. 2007 Jun 15;110(2):139-44 [17532054.001]
  • [Cites] Mol Hum Reprod. 2007 Jul;13(7):503-9 [17483545.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12451-6 [17640886.001]
  • [Cites] Curr Opin Gastroenterol. 2008 Mar;24(2):103-7 [18301257.001]
  • [Cites] Endocrinology. 2008 May;149(5):2261-9 [18202125.001]
  • [Cites] Infect Immun. 2004 Oct;72(10):5799-806 [15385480.001]
  • [Cites] Clin Obstet Gynecol. 1976 Mar;19(1):147-69 [815068.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1789-99 [15541453.001]
  • [Cites] Int Immunol. 2005 Jan;17(1):1-14 [15585605.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):548-56 [15509642.001]
  • [Cites] Hum Reprod. 2005 May;20(5):1372-8 [15695310.001]
  • [Cites] Hum Immunol. 2005 May;66(5):469-82 [15935884.001]
  • [Cites] Immunology. 2005 Aug;115(4):565-74 [16011525.001]
  • [Cites] Lancet. 2005 Aug 6-12;366(9484):491-505 [16084259.001]
  • [Cites] Chem Immunol Allergy. 2005;88:150-62 [16129944.001]
  • [Cites] Immunobiology. 2005;210(2-4):153-60 [16164022.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2840-7 [16364998.001]
  • [Cites] Endocrinology. 2006 Jan;147(1):562-70 [16223858.001]
  • [Cites] Reprod Biol Endocrinol. 2005;3:74 [16384532.001]
  • [Cites] J Immunol. 2006 May 15;176(10):5805-14 [16670286.001]
  • [Cites] Biol Reprod. 2006 Jun;74(6):1060-6 [16481591.001]
  • [Cites] Proc Am Thorac Soc. 2006 Jul;3(5):401-4 [16799081.001]
  • [Cites] Biol Reprod. 2006 Aug;75(2):176-82 [16672717.001]
  • [Cites] Cell Res. 2006 Aug;16(8):693-701 [16894359.001]
  • [Cites] Shock. 2006 Nov;26(5):430-7 [17047512.001]
  • [Cites] Hum Reprod. 2007 Feb;22(2):586-93 [17043100.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2918-22 [15087412.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17079-84 [14764599.001]
  • [Cites] Immunology. 2004 Jul;112(3):428-36 [15196211.001]
  • (PMID = 18775079.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / TLR3 protein, human; 0 / TLR4 protein, human; 0 / Toll-Like Receptor 3; 0 / Toll-Like Receptor 4
  • [Other-IDs] NLM/ PMC2543020
  •  go-up   go-down


51. Kubarek Ł, Jagodzinski PP: Epigenetic up-regulation of CXCR4 and CXCL12 expression by 17 beta-estradiol and tamoxifen is associated with formation of DNA methyltransferase 3B4 splice variant in Ishikawa endometrial adenocarcinoma cells. FEBS Lett; 2007 Apr 3;581(7):1441-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic up-regulation of CXCR4 and CXCL12 expression by 17 beta-estradiol and tamoxifen is associated with formation of DNA methyltransferase 3B4 splice variant in Ishikawa endometrial adenocarcinoma cells.
  • Increased risk for the development of endometrial cancer has been associated with unopposed oestrogen exposure, hyperoestrogenic factors, and a history of breast cancer treated long-term with tamoxifen (Tam).
  • Stromal cell-derived factor-1, currently named as CXCL12, is a chemokine that, via binding to CXCR4 receptor, activates several downstream effectors and signalling pathways responsible for proliferation, survival, and migration of cancer cells.
  • We observed that 17beta-estradiol (E2) and tamoxifen (Tam) increase the expression of CXCR4 and CXCL12 transcripts and proteins in oestrogen receptor positive (ER(+)) but not in negative (ER(-)02) Ishikawa endometrial adenocarcinoma (ISH) cell lines.
  • [MeSH-major] Adenocarcinoma / genetics. Antineoplastic Agents, Hormonal / pharmacology. Chemokines, CXC / genetics. DNA (Cytosine-5-)-Methyltransferase / metabolism. Endometrial Neoplasms / genetics. Epigenesis, Genetic / drug effects. Estradiol / pharmacology. Receptors, CXCR4 / genetics. Tamoxifen / pharmacology

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17362937.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Receptors, CXCR4; 094ZI81Y45 / Tamoxifen; 4TI98Z838E / Estradiol; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3B
  •  go-up   go-down


52. Natee J, Kietpeerakool C, Srisomboon J, Khunamornpong S, Suprasert P, Phongnarisorn C, Cheewakriangkrai C, Charoenkwan K, Siriaree S, Pantusart A: Clinicopathologic analysis of women with synchronous primary carcinomas of the endometrium and ovary: 10- year experience from Chiang Mai University Hospital. Asian Pac J Cancer Prev; 2006 Apr-Jun;7(2):234-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of women with synchronous primary carcinomas of the endometrium and ovary: 10- year experience from Chiang Mai University Hospital.
  • The aim of this study was to analyze the clinicopathologic features and survival outcomes of women with synchronous primary carcinomas of the endometrium and ovary that were treated at Chiang Mai University Hospital between January 1995 and December 2004.
  • These carcinomas accounted for 0.58% (95%CI=0.42-0.79%) of all gynecologic malignancies.
  • Median age at diagnosis was 49 years (range: 34-60 years).
  • The most common presenting symptom was abnormal uterine bleeding (42%), followed by a pelvic mass (30%).
  • Twenty-seven (62.8%, 95%CI= 46.7-77.0%) women had concordant endometrioid carcinomas of the endometrium and ovary.
  • There was no significant difference in survival outcomes among the women who had endometrioid/endometrioid histology and those who had other histological subtypes (P=0.674).
  • In conclusion, synchronous primary carcinomas of the endometrium and ovary, although uncommon, should be considered in differential diagnosis in premenopausal women presenting with abnormal uterine bleeding and ovarian tumors.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16839215.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


53. Papanas N, Giatromanolaki A, Galazios G, Maltezos E, Sivridis E: Endometrial carcinoma and diabetes revisited. Eur J Gynaecol Oncol; 2006;27(5):505-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma and diabetes revisited.
  • OBJECTIVE: To investigate whether endometrial adenocarcinomas are intrinsically different in diabetic as compared to non-diabetic patients.
  • METHODS: A series of 208 patients with histologically confirmed endometrial adenocarcinomas were divided into groups of diabetic (n = 63) and non-diabetic (n = 145) patients.
  • RESULTS: A history of a second neoplasia was significantly more frequent in diabetic than in non-diabetic patients (p = 0.001), but other endometrial cancer associated characteristics, such as tumor morphology, FIGO stage, obesity, hypertension, nulliparity, estrogen use and menopausal status did not differ between the groups.
  • CONCLUSIONS: A second neoplasia occurred significantly more frequently in diabetic than in non-diabetic patients with endometrial carcinoma, but long-term survival and other clinical and histological features were the same in the two groups.
  • These results indicate that endometrial adenocarcinoma is not intrinsically different in diabetic patients.
  • [MeSH-major] Adenocarcinoma / complications. Diabetes Complications. Endometrial Neoplasms / complications. Neoplasms, Second Primary / epidemiology

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139988.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


54. O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol; 2006 Jan;13(1):8-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in the female genital tract and its value in diagnosis.
  • Most cervical carcinomas of squamous, glandular, and small cell type are p16-positive.
  • In cervical glandular lesions, p16 is useful, as part of a panel, in the distinction between adenocarcinoma in situ (diffusely positive) and benign mimics, including tuboendometrial metaplasia and endometriosis, which are usually p16-negative or focally positive. p16 may be used, in combination with other markers, to distinguish between a cervical adenocarcinoma (diffuse positivity) and an endometrioid-type endometrial adenocarcinoma (negative or focally positive).
  • Some uterine serous carcinomas are diffusely positive.
  • Similarly, HPV-associated invasive squamous carcinomas are p16-positive, whereas the more common non-HPV-associated neoplasms are largely negative or focally positive.
  • In the uterus, p16 positivity is more common and widespread in leiomyosarcomas than leiomyomas, and this may be a useful aid to diagnosis, although problematic uterine smooth muscle neoplasms have not been extensively studied.
  • Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary ovarian adenocarcinomas of these morphologic subtypes has not been widely investigated.
  • Some ovarian serous carcinomas, similar to their uterine counterparts, are p16-positive.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Genital Neoplasms, Female / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Diagnosis, Differential. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Female. Genes, p16. Genitalia, Female / chemistry. Genitalia, Female / physiopathology. Humans. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / chemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics. Uterine Neoplasms / chemistry. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / classification. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462152.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 65
  •  go-up   go-down


55. Nayak TK, Hathaway HJ, Ramesh C, Arterburn JB, Dai D, Sklar LA, Norenberg JP, Prossnitz ER: Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers. J Nucl Med; 2008 Jun;49(6):978-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers.
  • Breast and endometrial cancers are the most common invasive malignancies in women, with more than 217,000 new diagnoses per year in the United States.
  • In this study, we describe a new structural class of neutral tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivatives for potential use in breast and endometrial cancer imaging.
  • Cell-binding studies were performed with human breast adenocarcinoma MCF-7 cells.
  • Biodistribution and SPECT/CT studies were performed with mice bearing MCF-7 and primary human endometrial tumors.
  • Despite high nonspecific uptake in the liver, significant receptor-mediated uptake was observed in target tissues and estrogen receptor-expressing tumors (0.67% for MCF-7 tumors and 0.77% for endometrial tumors).
  • CONCLUSION: We have characterized a novel neutral tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for potential use in breast and endometrial cancer imaging.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NANDROLONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2006 May;6(5):360-8 [16633364.001]
  • [Cites] Nat Chem Biol. 2006 Apr;2(4):207-12 [16520733.001]
  • [Cites] J Endocrinol. 2006 Aug;190(2):225-39 [16899557.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6359-66 [17085646.001]
  • [Cites] J Am Chem Soc. 2006 Nov 15;128(45):14476-7 [17090028.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):764-6 [17156828.001]
  • [Cites] Nucl Med Biol. 2007 Feb;34(2):205-10 [17307128.001]
  • [Cites] Am J Obstet Gynecol. 2007 Apr;196(4):386.e1-9; discussion 386.e9-11 [17403429.001]
  • [Cites] Hypertension. 2007 Jun;49(6):1358-63 [17452498.001]
  • [Cites] ACS Chem Biol. 2007 Aug 17;2(8):536-44 [17655271.001]
  • [Cites] Breast. 2007 Dec;16 Suppl 2:S105-13 [17719781.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1727-41 [15894099.001]
  • [Cites] Nucl Med Biol. 2000 Apr;27(3):269-78 [10832084.001]
  • [Cites] J Natl Cancer Inst. 2002 May 1;94(9):662-9 [11983754.001]
  • [Cites] Bioorg Med Chem. 2003 Nov 17;11(23):4977-89 [14604660.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):1-7 [14734659.001]
  • [Cites] Can J Biochem. 1968 Apr;46(4):299-302 [5690431.001]
  • [Cites] Endocrinology. 1971 Jan;88(1):175-9 [5099583.001]
  • [Cites] Annu Rev Physiol. 1975;37:273-302 [164819.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jan;77(1):328-32 [6928625.001]
  • [Cites] Biol Reprod. 1982 Sep;27(2):327-39 [6889895.001]
  • [Cites] J Steroid Biochem. 1983 Jun;18(6):635-41 [6191127.001]
  • [Cites] Life Sci. 1983 Nov 7;33(19):1933-8 [6316052.001]
  • [Cites] Cancer. 1986 Mar 15;57(6):1171-80 [3943040.001]
  • [Cites] Int J Rad Appl Instrum B. 1987;14(1):15-25 [3108199.001]
  • [Cites] J Nucl Med. 1991 Aug;32(8):1526-31 [1869973.001]
  • [Cites] Am J Physiol. 1992 Apr;262(4 Pt 2):R666-70 [1566933.001]
  • [Cites] Endocrinology. 1997 Mar;138(3):863-70 [9048584.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3B):1573-6 [9179196.001]
  • [Cites] Clin Cancer Res. 1996 Jun;2(6):933-9 [9816253.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):169-75 [15657363.001]
  • [Cites] Science. 2005 Mar 11;307(5715):1625-30 [15705806.001]
  • [Cites] Bioconjug Chem. 2005 Mar-Apr;16(2):255-64 [15769078.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii174-81 [15958453.001]
  • [Cites] Mol Cancer Ther. 2005 Jul;4(7):1065-75 [16020664.001]
  • [Cites] N Engl J Med. 2006 Jan 19;354(3):270-82 [16421368.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2793-9 [16682724.001]
  • (PMID = 18483091.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118743-01A2; United States / NIMH NIH HHS / MH / U54 MH074425; United States / NCI NIH HHS / CA / P30 CA118100; United States / NCI NIH HHS / CA / CA116662-02; United States / NIGMS NIH HHS / GM / S06 GM008136; United States / NCI NIH HHS / CA / R01 CA118743; United States / NCI NIH HHS / CA / R01 CA127731; United States / NCI NIH HHS / CA / R01 CA116662-02; United States / NIGMS NIH HHS / GM / GM08136; United States / NCI NIH HHS / CA / CA116662; United States / NCI NIH HHS / CA / CA118743-01A2; United States / NIMH NIH HHS / MH / MH074425; United States / NCI NIH HHS / CA / R01 CA116662; United States / NCI NIH HHS / CA / CA127731
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 7-fluoromethyldihydrotestosterone; 0 / 7-fluoromethylnortestosterone; 0 / Radiopharmaceuticals; 0 / Receptors, Estrogen; 08J2K08A3Y / Dihydrotestosterone; 6PG9VR430D / Nandrolone
  • [Other-IDs] NLM/ NIHMS52064; NLM/ PMC2435083
  •  go-up   go-down


56. Heubner M, Wimberger P, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W: The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer. Anticancer Res; 2009 Aug;29(8):3449-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer.
  • BACKGROUND: Recent studies proposed L1CAM (L1 cell adhesion molecule) expression as a negative prognostic marker in epithelial ovarian cancer (EOC).
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Serous / genetics. Endometrial Neoplasms / genetics. Neural Cell Adhesion Molecule L1 / genetics. Ovarian Neoplasms / genetics. Polymorphism, Single Nucleotide / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661372.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neural Cell Adhesion Molecule L1
  •  go-up   go-down


57. Areia A, Branco M, Frutuoso C, de Oliveira CF: Endometrial adenocarcinoma after endometrial ablation. A case report. Eur J Gynaecol Oncol; 2006;27(4):432-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma after endometrial ablation. A case report.
  • The authors present a case of endometrial adenocarcinoma after endometrial ablation, emphasizing the importance of close surveillance of these patients, patient selection and education.
  • Even patients with none of the risk factors for endometrial cancer or contraindications to endometrial ablation should be checked carefully.
  • [MeSH-major] Adenocarcinoma / diagnosis. Catheter Ablation. Endometrial Neoplasms / diagnosis. Endometrium / pathology. Uterine Hemorrhage / therapy

  • MedlinePlus Health Information. consumer health - Vaginal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009646.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


58. Liu H, Yan Z, Liao G, Yin H, Xie X: [Clinicopathologic characteristics, diagnosis, and treatment of 30 patients with hereditary nonpolyposis colorectal cancer]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug;34(8):757-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic characteristics, diagnosis, and treatment of 30 patients with hereditary nonpolyposis colorectal cancer].
  • OBJECTIVE: To explore the clinicopathologic and molecular characteristics of hereditary nonpolyposis colorectal cancer (HNPCC), and to improve the level of diagnosis and treatments of HNPCC.
  • METHODS: Thirty HNPCC patients (HNPCC group) who were treated in Xiangya Hospital were retrospectively analyzed, and 25 patients with sporadic colorectal cancer in the same duration were randomly chosen as a control group.
  • The rate of proximal colonic tumor the occurrence of multiple tumors, and the proportion of well differentiated adenocarcinoma in the HNPCC group were all higher than those in the control group (P<0.05).
  • The prognosis of HNPCC patients was comparable with that of patients with sporadic colorectal cancer (P>0.05).
  • The accuracy of diagnosis can be improved by combining the detection of MMR gene.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Adenocarcinoma. Colorectal Neoplasms, Hereditary Nonpolyposis. MutS Homolog 2 Protein / genetics. Mutation. Nuclear Proteins / genetics
  • [MeSH-minor] Aged. Case-Control Studies. Endometrial Neoplasms / pathology. Female. Humans. Male. Middle Aged. Neoplasms, Second Primary / pathology. Retrospective Studies

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734583.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


59. Fournier M, Stoeckle E, Guyon F, Brouste V, Thomas L, MacGrogan G, Floquet A: Lymph node involvement in epithelial ovarian cancer: sites and risk factors in a series of 355 patients. Int J Gynecol Cancer; 2009 Nov;19(8):1307-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node involvement in epithelial ovarian cancer: sites and risk factors in a series of 355 patients.
  • OBJECTIVES: To perform a cartography of lymph node metastases in epithelial ovarian cancer and to determine predictive factors of lymph node metastases.
  • METHOD: The charts of 355 patients with epithelial ovarian cancer who underwent lymphadenectomy during a primary (n = 252) or secondary debulking surgery (n = 103) were analyzed.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / secondary. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / secondary. Lymph Nodes / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009882.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Buccoliero AM, Gheri CF, Castiglione F, Garbini F, Barbetti A, Fambrini M, Bargelli G, Pappalardo S, Taddei A, Boddi V, Scarselli GF, Marchionni M, Taddei GL: Liquid-based endometrial cytology: cyto-histological correlation in a population of 917 women. Cytopathology; 2007 Aug;18(4):241-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liquid-based endometrial cytology: cyto-histological correlation in a population of 917 women.
  • OBJECTIVE: Liquid-based cytology, because of its capacity to reduce the obscuring factors and to provide thin-layer specimens, represents an opportunity to reevaluate endometrial cytology.
  • In order to assess the utility of the liquid-based method in endometrial diagnosis, we evaluated its accuracy in comparison with histology.
  • After providing informed consent, all the women proceeded sequentially to hysteroscopy, endometrial cytology and then biopsy endometrial sampling.
  • At biopsy 25 (3%) women had adenocarcinoma, 5 (1%) had adenomatous atypical hyperplasia and 21 (2%) had simple non atypical hyperplasia.
  • At cytology two adenocarcinomas and one adenomatous atypical hyperplasia were underrated as atypical hyperplasias and as non-atypical hyperplasia; two simple non-atypical hyperplasias were reported as negative; and eight cases were false positive (non-atypical hyperplasia at cytology, negative at biopsy).
  • CONCLUSIONS: We concluded that endometrial cytology may be an efficient diagnostic method.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Endometrium / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy / methods. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / pathology. Cytodiagnosis / methods. Endometrial Hyperplasia / diagnosis. Endometrial Hyperplasia / pathology. Female. Humans. Hysteroscopy. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity. Specimen Handling / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559564.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Shou HF, Ni J, Zhu T, Chen JH, Zhang X, Xu XX, Chen L, Yu H: [Association between endometrial cancer and metabolic syndrome]. Zhonghua Fu Chan Ke Za Zhi; 2010 Feb;45(2):128-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association between endometrial cancer and metabolic syndrome].
  • OBJECTIVE: To study the association between endometrioid uterine carcinomas and metabolic syndrome (MS).
  • METHODS: A retrospective study was conducted on 123 patients who were admitted in Department of Gynecology Oncology, Zhejiang Cancer Hospital (study group) and 90 healthy women (control group) with matching age from Jan.
  • The percentage of HDL (< 1.30 mmol/L) was higher in study group than that in control group (63.4% vs. 32.2%, P < 0.05). (2) There were not significant difference for the clinical stage, pathological type, grades between patients with or without MS in study group (P > 0.05). (3) The Logistic multivariate survival analysis shown that central obesity, higher TG, lower HDL and abnormal plasma glucose were independent risk factors for endometrioid uterine carcinomas coupled with MS (P < 0.05).
  • CONCLUSION: Metabolic syndrome is marginally associated with an increased risk of endometrioid uterine carcinomas, which may be the new point to screen, prevention and treatment endometrioid uterine carcinomas.
  • [MeSH-major] Adenocarcinoma / etiology. Endometrial Neoplasms / etiology. Metabolic Syndrome X / complications. Obesity / complications

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420784.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Lipoproteins, HDL; 0 / Triglycerides
  •  go-up   go-down


62. Ramirez PT, Frumovitz M, Milam MR, Deavers M, dos Reis R, Iyer RB, Bhosale P, Schmeler KM: Limited utility of magnetic resonance imaging in determining the primary site of disease in patients with inconclusive endometrial biopsy. Int J Gynecol Cancer; 2010 Nov;20(8):1344-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited utility of magnetic resonance imaging in determining the primary site of disease in patients with inconclusive endometrial biopsy.
  • OBJECTIVE: To evaluate the utility of preoperative magnetic resonance imaging (MRI) in determining whether primary disease site is cervical or endometrial in patients with inconclusive preoperative endometrial biopsy.
  • METHODS: We retrospectively identified all patients who underwent pelvic MRI and who had a preoperative diagnosis of cervical or endometrial cancer at MD Anderson Cancer Center between 1990 and 2006.
  • The subset in which endometrial biopsy did not clarify the primary disease site was analyzed.
  • RESULTS: A total of 168 patients who underwent MRI who had a preoperative diagnosis of cervical or endometrial cancer were identified.
  • Of these patients, 51 had an inconclusive endometrial biopsy.
  • Magnetic resonance imaging suggested an endometrial primary tumor without cervical invasion in 28 patients, of whom 21 (75%) actually had such a tumor and 7 had an endometrial primary tumor with cervical invasion.
  • Magnetic resonance imaging suggested an endometrial primary tumor with cervical invasion in 3 patients, all of whom had such a tumor.
  • Magnetic resonance imaging suggested a cervical primary tumor in 6 patients, of whom 5 had such a tumor and 1 had an endometrial primary tumor without cervical invasion.
  • Magnetic resonance imaging was inconclusive (did not clarify primary disease site or no lesion visualized) in 14 (27%) of 51 patients, 6 of whom had an endocervical primary tumor or an endometrial tumor with cervical involvement.
  • CONCLUSION: Preoperative MRI in patients with inconclusive endometrial biopsy is inaccurate or unhelpful in nearly half of patients.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiography. Magnetic Resonance Imaging / methods. Neoplasms, Unknown Primary / radiography
  • [MeSH-minor] Algorithms. Biopsy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radiography. Carcinoma, Endometrioid / secondary. Diagnostic Techniques, Obstetrical and Gynecological. Female. Humans. Neoplasm Staging. Predictive Value of Tests. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21051975.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS650170; NLM/ PMC4361062
  •  go-up   go-down


63. Boruban MC, Jaishuen A, Sirisabya N, Li Y, Zheng HG, Deavers MT, Kavanagh JJ: Ovarian endometriosis associated with carcinoma and sarcoma: case report. Eur J Gynaecol Oncol; 2008;29(4):393-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian endometriosis associated with carcinoma and sarcoma: case report.
  • Endometriosis is a common clinical disorder that shares certain characteristics, metastasis and recurrence, with malignant neoplasms.
  • Most malignant ovarian tumors arising from endometriosis are clear cell carcinoma or endometrioid adenocarcinoma.
  • Here, we report the case of a 32-year-old woman who presented with infertility and a pelvic mass.
  • The pathologic findings revealed bilateral endometrioid adenofibroma of low malignant potential, which was associated with endometrioid intraepithelial carcinoma in the left ovary and high-grade sarcoma in the right ovary.
  • The optimal treatment for endometriosis-associated ovarian cancer depends on the type of malignancy; simultaneously occurring multiple tumor types should be treated individually.
  • [MeSH-major] Carcinoma / etiology. Endometriosis / complications. Ovarian Diseases / complications. Ovarian Neoplasms / etiology. Sarcoma / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / complications. Endometrial Neoplasms / drug therapy. Female. Humans. Neoplasms, Multiple Primary


64. Adamovic T, Trossö F, Roshani L, Andersson L, Petersen G, Rajaei S, Helou K, Levan G: Oncogene amplification in the proximal part of chromosome 6 in rat endometrial adenocarcinoma as revealed by combined BAC/PAC FISH, chromosome painting, zoo-FISH, and allelotyping. Genes Chromosomes Cancer; 2005 Oct;44(2):139-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogene amplification in the proximal part of chromosome 6 in rat endometrial adenocarcinoma as revealed by combined BAC/PAC FISH, chromosome painting, zoo-FISH, and allelotyping.
  • The inbred BDII rat is a valuable experimental model for the genetic analysis of endometrial adenocarcinoma (EAC).
  • In addition, the RNO6q11-q16 segment was analyzed by fluorescence in situ hybridization with probes representing 12 cancer-related genes in the region.
  • Five tumors (two of which also had HSRs) exhibited a selective increase of the RNO6q11-q16 segment, sometimes in conjunction with moderate amplification of one or a few genes.
  • [MeSH-major] Adenocarcinoma / genetics. Alleles. Chromosome Mapping. Chromosome Painting. Chromosomes, Artificial, Bacterial. Chromosomes, Artificial, P1 Bacteriophage. Endometrial Neoplasms / genetics. Oncogenes

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942940.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


65. Németh J, Németh Z, Tátrai P, Péter I, Somorácz A, Szász AM, Kiss A, Schaff Z: High expression of claudin-1 protein in papillary thyroid tumor and its regional lymph node metastasis. Pathol Oncol Res; 2010 Mar;16(1):19-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Claudins, known as major contributors in the formation of the tight junction, are differentially expressed in malignant tumors as compared to the corresponding healthy tissues.
  • Altered expression of claudin-1 has been reported in several tumor types including endometrial, papillary renal cell and colonic carcinoma, and increased claudin-1 mRNA levels have been observed in papillary thyroid carcinoma (PTC).
  • Samples included 19 PTCs, ten cases of corresponding regional lymph node metastasis, eight papillary microcarcinomas (PMC), 17 follicular thyroid carcinomas (FTC) and 19 follicular adenomas (FA).
  • On the other hand, we found weak or no claudin-1 expression in any of the FA and FTC cases or peritumoral non-malignant thyroid tissues.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Membrane Proteins / biosynthesis. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Biophys Mol Biol. 2003 Jan;81(1):1-44 [12475568.001]
  • [Cites] Eur J Endocrinol. 2008 Mar;158(3):375-84 [18299472.001]
  • [Cites] Mod Pathol. 2008 Jan;21(1):22-30 [17962811.001]
  • [Cites] Am J Respir Crit Care Med. 2009 Jan 15;179(2):123-33 [18787218.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] Hum Pathol. 2005 Feb;36(2):162-9 [15754293.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):24-30 [11172291.001]
  • [Cites] Int J Mol Med. 2008 Nov;22(5):645-9 [18949385.001]
  • [Cites] World J Gastroenterol. 2008 Aug 21;14(31):4943-8 [18756604.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1539-50 [9647647.001]
  • [Cites] J Surg Res. 2008 Nov;150(1):49-52 [17996901.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):511-8 [15475928.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1765-76 [15965503.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1778(3):588-600 [17916321.001]
  • [Cites] Hum Pathol. 2006 May;37(5):555-61 [16647953.001]
  • [Cites] Nature. 2008 Sep 25;455(7212):547-51 [18794900.001]
  • [Cites] World J Gastroenterol. 2008 Jun 28;14(24):3866-71 [18609711.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1778(3):631-45 [18036336.001]
  • [Cites] Thyroid. 2006 Feb;16(2):161-75 [16676402.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3433-40 [12107263.001]
  • [Cites] Mod Pathol. 2008 May;21 Suppl 2:S37-43 [18437172.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):7035-42 [18981000.001]
  • [Cites] BMC Cancer. 2006 Jul 12;6:186 [16836752.001]
  • [Cites] Virchows Arch. 2007 May;450(5):549-57 [17429687.001]
  • [Cites] Expert Rev Mol Med. 2006 Aug 04;8(18):1-11 [16887048.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Apr 25;57(6):919-28 [15820559.001]
  • [Cites] Histopathology. 2002 Oct;41(4):357-62 [12383219.001]
  • [Cites] Exp Mol Pathol. 2007 Feb;82(1):91-4 [17123508.001]
  • [Cites] Histopathology. 2005 May;46(5):551-60 [15842637.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):591-8 [16797678.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3531-9 [15337802.001]
  • [Cites] Oncol Res. 2001;12(11-12):469-76 [11939410.001]
  • [Cites] Endokrynol Pol. 2006;57 Suppl A:18-25 [17091452.001]
  • (PMID = 19578981.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Membrane Proteins
  •  go-up   go-down


66. Lim MC, Lee SM, Lee J, Choi HJ, Lee S, Huh CY, Park SY: Endometrioid adenocarcinoma in urethrovaginal septum: a diagnostic pitfall. J Korean Med Sci; 2009 Feb;24(1):162-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma in urethrovaginal septum: a diagnostic pitfall.
  • Primary endometrioid adenocarcinoma developed at urethrovaginal septum has not been reported.
  • A pinpoint ulceration at slightly elevated anterior vaginal wall was found and biopsy revealed endometrioid adenocarcinoma.
  • Microscopic finding of the pathology revealed endometrioid adenocarcinoma.
  • This is the first reported case of extraovarian endometrioid adenocarcinoma developed at the urethrovaginal septum.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis. Urethral Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1970 Aug;36(2):251-6 [5428492.001]
  • [Cites] Gynecol Oncol. 1984 Jan;17(1):58-63 [6420243.001]
  • [Cites] Hinyokika Kiyo. 1988 Apr;34(4):696-700 [3041781.001]
  • [Cites] Obstet Gynecol. 2006 Sep;108(3 Pt 2):753-5 [17018491.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(1):39-41 [9476057.001]
  • [Cites] Jpn J Clin Oncol. 2005 Mar;35(3):154-7 [15741306.001]
  • [Cites] Gynecol Oncol. 1989 Aug;34(2):232-6 [2666285.001]
  • (PMID = 19270832.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2650998
  • [Keywords] NOTNLM ; Carcinoma, Endometrioid / Urethrovaginal Septum
  •  go-up   go-down


67. Karateke A, Haliloglu B, Atay V, Gurbuz A, Kir G: A case of microglandular adenocarcinoma of the endometrium. Gynecol Oncol; 2005 Dec;99(3):778-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of microglandular adenocarcinoma of the endometrium.
  • BACKGROUND: Microglandular adenocarcinoma is a rare type of endometrium carcinoma and had some potential diagnostic problems with difficulties in discriminating from some malign and benign lesions of cervix.
  • CASE REPORT: A 70-year-old woman misdiagnosed as cervical adenocarcinoma was referred to our clinic, and the lesion was ultimately evaluated as microglandular adenocarcinoma in repeat of endometrial curettage specimen.
  • Postoperatively, histopathologic examination of specimen revealed grade 1 microglandular adenocarcinoma.
  • To our best knowledge, this is the twelfth case of uterine carcinoma simulating microglandular hyperplasia in the literature.
  • CONCLUSION: Because microglandular adenocarcinoma can be confused with benign lesions like microglandular hyperplasia and malignant lesions of cervix, we aim to discuss the clinical, demographic and immunohistochemical characteristics of the patients with microglandular adenocarcinoma useful in differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Endometrial Hyperplasia / diagnosis. Endometrial Hyperplasia / metabolism. Endometrial Hyperplasia / pathology. Female. Humans. Immunohistochemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16229880.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Taylor SE, Patel II, Singh PB, Nicholson CM, Stringfellow HF, Gopala Krishna RK, Matanhelia SS, Martin-Hirsch PL, Martin FL: Elevated oestrogen receptor splice variant ERαΔ5 expression in tumour-adjacent hormone-responsive tissue. Int J Environ Res Public Health; 2010 11;7(11):3871-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Susceptibility to prostate or endometrial cancer is linked with obesity, a state of oestrogen excess.
  • Such micro-environmental regulation may modulate cancer initiation and/or progression mechanisms.
  • Real-time reverse transcriptase (RT) polymerase chain reaction (PCR) was used to quantitatively assess the levels of four ER splice variants (ERαΔ3, ERαΔ5, ERβ2 and ERβ5), plus the full-length parent isoforms ERα and ERβ1, in high-risk [tumour-adjacent prostate (n = 10) or endometrial cancer (n = 9)] vs. low-risk [benign prostate (n = 12) or endometrium (n = 9)], as well as a comparison of UK (n = 12) vs. Indian (n = 15) benign prostate.
  • This small pilot study demonstrates the ubiquitous nature of ER splice variants in these tissue sites and suggests that ERαΔ5 may be involved in progression of prostate adenocarcinoma.
  • [MeSH-major] Endometrial Neoplasms / genetics. Endometrium / metabolism. Estrogen Receptor alpha / genetics. Neoplasms, Hormone-Dependent / genetics. Prostate / metabolism. Prostatic Neoplasms / genetics. RNA Splicing

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Endocrinol. 2000 May;14(5):634-49 [10809228.001]
  • [Cites] Nat Protoc. 2010 Nov;5(11):1748-60 [21030951.001]
  • [Cites] Mutagenesis. 2002 Jul;17(4):345-52 [12110632.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):783-7 [15170658.001]
  • [Cites] Am J Obstet Gynecol. 2004 Aug;191(2):626-33; discussion 633-4 [15343251.001]
  • [Cites] Cancer Lett. 2004 Nov 8;215(1):101-12 [15374639.001]
  • [Cites] J Natl Cancer Inst. 1995 May 3;87(9):652-61 [7752270.001]
  • [Cites] Jpn J Cancer Res. 1998 Apr;89(4):355-60 [9617339.001]
  • [Cites] Mol Hum Reprod. 1998 Jul;4(7):641-7 [9701786.001]
  • [Cites] Endocrine. 2005 Aug;27(3):227-38 [16230778.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jan;95(1):37-43 [16267616.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2006 Apr;20(2):227-51 [16543119.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13162-7 [16938840.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):407-12 [17561234.001]
  • [Cites] Obstet Gynecol. 2008 Feb;111(2 Pt 1):436-47 [18238985.001]
  • [Cites] Eur J Cancer. 2008 May;44(7):928-36 [18381236.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):815-25 [18505969.001]
  • [Cites] Mol Hum Reprod. 2008 Nov;14(11):655-63 [18849443.001]
  • [Cites] Prostate. 2009 Apr 1;69(5):505-19 [19143007.001]
  • [Cites] BJOG. 2010 Feb;117(3):348-55 [20015310.001]
  • [Cites] Cancer Lett. 2010 Feb 28;288(2):133-48 [19608332.001]
  • [Cites] Asian J Androl. 2010 Mar;12(2):203-14 [19935673.001]
  • [Cites] Cancer Lett. 2010 Jul 28;293(2):133-43 [20080335.001]
  • [Cites] Endocr Relat Cancer. 2010 Sep;17(3):675-89 [20501637.001]
  • [Cites] Prostate. 2010 Oct 1;70(14):1586-99 [20687231.001]
  • [Cites] Annu Rev Physiol. 2002;64:93-127 [11826265.001]
  • (PMID = 21139866.001).
  • [ISSN] 1660-4601
  • [Journal-full-title] International journal of environmental research and public health
  • [ISO-abbreviation] Int J Environ Res Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Complementary; 0 / Estrogen Receptor alpha
  • [Other-IDs] NLM/ PMC2996214
  • [Keywords] NOTNLM ; endometrial cancer (major topic) / oestrogen receptor (major topic) / prostate cancer (major topic) / real-time RT PCR (major topic) / splice variant (major topic)
  •  go-up   go-down


69. Shigemitsu A, Furukawa N, Koike N, Kobayashi H: Endometrial cancer diagnosed by the presence of bone metastasis and treated with zoledronic Acid: a case report and review of the literature. Case Rep Oncol; 2010 Sep;3(3):471-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial cancer diagnosed by the presence of bone metastasis and treated with zoledronic Acid: a case report and review of the literature.
  • Bone metastasis from endometrial cancer is rare.
  • We report a case of endometrial cancer which was diagnosed by the presence of bone metastasis and treated with zoledronic acid.
  • Computed tomography revealed an enlarged uterus; the patient consequently consulted a gynecologist.
  • Histological sections of an endometrial biopsy showed endometrioid adenocarcinoma.
  • A moderately differentiated endometrioid adenocarcinoma was expressed in the corpus.
  • Histopathological examination of the bone biopsy also revealed adenocarcinoma.
  • The final diagnosis was stage IVB endometrial cancer with bone and lung metastasis.
  • Radiotherapy was then given for the right ischial metastasis after the ninth course of zoledronic acid therapy because the metastasis site had increased and the possibility of a pathological fracture had risen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):281-4 [12068176.001]
  • [Cites] Breast. 2003 Aug;12 Suppl 2:S30-6 [14659141.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Gynecol Oncol. 1992 May;45(2):142-6 [1592280.001]
  • [Cites] Clin Exp Metastasis. 2007;24(2):87-92 [17364220.001]
  • [Cites] J Foot Ankle Surg. 2005 Nov-Dec;44(6):462-5 [16257676.001]
  • [Cites] BJU Int. 2009 Mar;103(5):620-4 [18990143.001]
  • [Cites] J Gynecol Oncol. 2009 Jun;20(2):67-71 [19590716.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2779-81 [8194019.001]
  • [Cites] Gynecol Oncol. 1990 Nov;39(2):108-14 [2227582.001]
  • [Cites] Ann Surg. 1940 Jul;112(1):138-49 [17857618.001]
  • (PMID = 21611145.001).
  • [ISSN] 1662-6575
  • [Journal-full-title] Case reports in oncology
  • [ISO-abbreviation] Case Rep Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3100269
  • [Keywords] NOTNLM ; Bisphosphonates / Bone metastasis / Endometrial cancer
  •  go-up   go-down


70. Falany JL, Falany CN: Regulation of SULT1E1 expression in Ishikawa adenocarcinoma cells by tibolone. Steroids; 2006 Oct;71(10):880-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of SULT1E1 expression in Ishikawa adenocarcinoma cells by tibolone.
  • Tibolone is used therapeutically as a hormone replacement agent and has beneficial effects on osteoporosis and hot flushes as well as libido in post-menopausal women without stimulatory effects in the breast and endometrium.
  • The lack of effect in the endometrium is due in part to the tissue specific sulfation of tibolone and its active metabolites in endometrial tissues.
  • Human endometrium and Ishikawa endometrial adenocarcinoma cells express SULT1E1 that efficiently sulfates both 3-OH tibolone metabolites and has trace activity with tibolone but no activity with the Delta4-isomer.
  • These results indicate that the lack of endometrial stimulation involves induction of SULT1E1 and the selective sulfation and inactivation of the estrogenic 3-OH tibolones and interconversion of the tibolone metabolites to generate the progestagenic non-sulfated Delta4-isomer.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857224.001).
  • [ISSN] 0039-128X
  • [Journal-full-title] Steroids
  • [ISO-abbreviation] Steroids
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM38953
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Norpregnenes; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.4 / estrone sulfotransferase; FF9X0205V2 / tibolone
  •  go-up   go-down


71. Patel A, Thampy N, Hemming D, Naik R: A clinical review of borderline glandular cells reported on liquid-based cervical cytology. BJOG; 2010 Aug;117(9):1051-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASURES: Final histological diagnosis.
  • Twenty-seven women (39.1%) had premalignant or malignant lesions, five (7.2%) had cancers and 22 (31.9%) had intraepithelial neoplasia, 19 (27.5%) of which were cervical squamous intraepithelial neoplasia (CIN) and three (4.3%) of which were cervical glandular intraepithelial neoplasia (CGIN).
  • No women under 35 years of age with normal and satisfactory colposcopy had premalignant or malignant lesions.
  • Despite normal and satisfactory colposcopy, three women over 35 years had significant lesions: one high-grade CIN, one CGIN and one squamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Endometrial Neoplasms / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


72. Chiaffarino F, Parazzini F, Bosetti C, Franceschi S, Talamini R, Canzonieri V, Montella M, Ramazzotti V, Franceschi S, La Vecchia C: Risk factors for ovarian cancer histotypes. Eur J Cancer; 2007 May;43(7):1208-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for ovarian cancer histotypes.
  • To analyse the risk factors for different histologic types of ovarian cancer, we conducted a case-control study.
  • The cases included 750 women with incident, histologically confirmed invasive epithelial ovarian cancer subdivided into: 493 serous, 81 mucinous, 78 endometrioid, and 98 other histologies.
  • The odds ratios for women with three or more births, in comparison with nulliparae, were 0.6 for serous, 0.4 for endometrioid, 1.0 for mucinous and 0.7 for other histological types of ovarian cancer.
  • Family history of ovarian/breast cancer was associated to the risk of all ovarian cancer types, except mucinous ones.
  • Selected dietary factors were less strongly directly (meat and starch), or inversely (fish and vitamin E) related to mucinous than to other histological types of ovarian cancer.
  • High occupational physical activity was inversely related to the risk of ovarian cancer, with no heterogeneity across histologies.
  • In conclusion, the association of reproductive factors and of selected dietary habits was weaker for mucinous ovarian cancer than for other histologic types.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376671.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


73. Yangmei S, Xiang H, Hongxin D, Hanshuo Y, Feng P, Yuping X, Yuquan W, Xia Z: Expression of human Biot2 and its potential function on carcinogenesis in endometrial cancer. Acta Obstet Gynecol Scand; 2007;86(12):1503-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of human Biot2 and its potential function on carcinogenesis in endometrial cancer.
  • We wanted to study the expression profile and reveal the function of its human homologous gene (human Biot2, hBiot2) on carcinogenesis in endometrial cancer.
  • Using real-time RT-PCR, we tested different expression quantities of hBiot2 between an endometrial cancer group and a normal endometrium group, between different histological grading groups in endometrial cancer, and between different stage groups during the menstrual cycle.
  • RNA-RNA ISH tested the expression location of hBiot2 in normal and cancer tissues.
  • Normal organs expressing hBiot2 in infants, did not express hBiot2 in adults. hBiot2 expression was higher in endometrial cancer tissue compared to normal endometrium tissue. hBiot2 expression was higher in the Grade 2-3 group with endometrial cancer compared to the Grade 1 group, and it was higher in the proliferative phase than in the secretory phase of a normal endometrium. hBiot2 was expressed mainly in the parenchymal cells.
  • The expression difference of hBiot2 between infants and adults, cancerous and normal tissues, different histological gradings in endometrial cancer, different stages during the menstrual cycle in the normal endometrium suggests that hBiot2 may have the potential to induce carcinogenesis in endometrial cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Neoplasm Proteins / biosynthesis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027117.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Neoplasm
  •  go-up   go-down


74. van der Horst C, Evans AJ: Peritoneal keratin granulomas complicating endometrial carcinoma: a report of two cases and review of the literature. Int J Gynecol Cancer; 2008 May-Jun;18(3):549-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal keratin granulomas complicating endometrial carcinoma: a report of two cases and review of the literature.
  • Squamous differentiation in endometrial adenocarcinoma is common.
  • Keratin granulomas accompanied by viable adenocarcinoma cells are regarded as conventional metastatic foci.
  • However, the significance of keratin granulomas without accompanying viable adenocarcinoma cells is difficult to ascertain.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Granuloma / pathology. Keratins / metabolism. Peritoneal Diseases / pathology

  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645505.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 8
  •  go-up   go-down


75. Osório-Costa F, Rocha GZ, Dias MM, Carvalheira JB: Epidemiological and molecular mechanisms aspects linking obesity and cancer. Arq Bras Endocrinol Metabol; 2009 Mar;53(2):213-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiological and molecular mechanisms aspects linking obesity and cancer.
  • About 25% of cancer cases globally are due to excess weight and a sedentary lifestyle.
  • Here, we present a review of epidemiological and molecular evidences linking obesity and cancer--particularly colorectal, post-menopausal breast, endometrial, pancreatic, high grade prostate, hepatocellular, gallbladder, kidney and esophageal adenocarcinoma.
  • The expected striking increase in the incidence of cancer in the near future related to obesity turns the knowledge of this field of great impact as it is needed to the development of strategies to prevent and treat this disease.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19466214.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  • [Number-of-references] 116
  •  go-up   go-down


76. Oman SA, Ballinger L, Cerilli LA: Small cell carcinoma: arising in Lynch syndrome: a previously undocumented occurrence. Int J Surg Pathol; 2009 Feb;17(1):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma: arising in Lynch syndrome: a previously undocumented occurrence.
  • Lynch syndrome is a genetic cancer predisposition syndrome caused by an inherited defect in 1 of 4 DNA mismatch repair genes (mutL homolog 1, mutS homolog 2, mutS homolog 6, and postmeiotic segregation 2).
  • Despite the theoretically increased risk in all tissues, Lynch syndrome exhibits tissue specificity, with a particular tendency among affected individuals to develop colorectal and endometrial cancer at a young age.
  • A growing body of evidence exists to support an association between mismatch repair mutations and a growing spectrum of hereditary nonpolyposis colon cancer-associated neoplasms.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Colonic Neoplasms / diagnosis. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. Mediastinal Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adult. DNA Mismatch Repair / genetics. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Endometrial Neoplasms / secondary. Female. Genetic Predisposition to Disease. Humans. Pedigree

  • Genetic Alliance. consumer health - Lynch syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480399.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Balendiran GK, Martin HJ, El-Hawari Y, Maser E: Cancer biomarker AKR1B10 and carbonyl metabolism. Chem Biol Interact; 2009 Mar 16;178(1-3):134-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer biomarker AKR1B10 and carbonyl metabolism.
  • A member of the aldo-keto reductase (AKR) protein superfamily, AKR1B10, is overexpressed in human liver cancers as well as in many adenocarcinoma cases due to smoking.
  • AKR1B10 is also detected in instances of cervical and endometrial cancer in uterine cancer patients.
  • In addition, AKR1B10 has been identified as a biomarker for non-small-cell lung cancer by a combined bioinformatics and clinical analysis.
  • Furthermore, in breast cancer cells, fatty acid biosynthesis is regulated by AKR1B10.
  • The anticancer drug daunorubicin, which is currently used in the clinical treatment of various forms of cancer, is converted by AKR1B10 to daunorubicinol with a K(m) and k(cat) of 1.1+/-0.18 mM and 1.4+/-0.16 min(-1), respectively.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Fenofibrate .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028477.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R15 DK085496
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Enzyme Inhibitors; EC 1.1.1.- / AKR1B10 protein, human; EC 1.1.1.21 / Aldehyde Reductase; U202363UOS / Fenofibrate
  •  go-up   go-down


78. Kurman RJ, McConnell TG: Precursors of endometrial and ovarian carcinoma. Virchows Arch; 2010 Jan;456(1):1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursors of endometrial and ovarian carcinoma.
  • This review discusses precursor lesions of endometrial and ovarian carcinoma with an emphasis on the unique molecular alterations that have led to the development of binary classification schemes for tumors of both the endometrium and ovary.
  • While such a system is well established for endometrial carcinoma, only recently has a binary classification scheme been proposed for ovarian carcinoma.
  • For both, the morphologic and molecular genetic-defining characteristics of their respective precursor lesions are described in detail.
  • Furthermore, similarities and differences of the precursor lesions of specific tumors of these two genital tract organs are also addressed with a brief discussion of the clinical implications of their diagnosis.
  • [MeSH-major] Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / pathology. Female. Humans. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):81-6 [7557621.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5308-14 [1913654.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):209-17 [11161379.001]
  • [Cites] Jpn J Cancer Res. 1999 Jan;90(1):55-9 [10076565.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3254-8 [9699651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961-5 [8506342.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2263-9 [18369088.001]
  • [Cites] Gynecol Oncol. 1992 Jul;46(1):51-4 [1634141.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):314-21 [11109159.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):779-85 [16721043.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1818-27 [12932658.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] Cancer Res. 1998 May 15;58(10 ):2095-7 [9605750.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):264-8 [8088602.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):207-23 [15306933.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):238-44 [8631545.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92 (11):924-30 [10841828.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):403-12 [4005805.001]
  • [Cites] Gynecol Oncol. 2000 Apr;77(1):55-65 [10739691.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Histopathology. 1995 Oct;27(4):367-71 [8847068.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1318-27 [8413413.001]
  • [Cites] Am J Pathol. 1991 Oct;139(4):777-85 [1656759.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23 ):13513-8 [9811831.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):614-24 [16699316.001]
  • [Cites] Hum Pathol. 2000 May;31(5):539-57 [10836293.001]
  • [Cites] Arch Pathol Lab Med. 1981 Nov;105(11):615-8 [6895302.001]
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):103-14 [17413975.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):883-7 [16806438.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):182-8 [7856726.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):378-81 [12893203.001]
  • [Cites] Am J Surg Pathol. 1992 Jun;16(6):600-10 [1599038.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 17;86(16):1216-21 [8040889.001]
  • [Cites] Am J Surg Pathol. 2009 Jun;33(6):844-53 [19342944.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jul;27(3):318-25 [18580308.001]
  • [Cites] Anal Quant Cytol Histol. 1986 Mar;8(1):46-8 [3954843.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(4):389-92 [17009632.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1319-30 [8898836.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):177-85 [9006334.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1895-8 [11395362.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):37-41 [12496696.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1088-91 [10880552.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6915-8 [15466181.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):319-31 [15494858.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1088-95 [9506354.001]
  • [Cites] J Pathol. 2004 Mar;202(3):336-40 [14991899.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7052-6 [11156411.001]
  • [Cites] Am J Obstet Gynecol. 1993 Jul;169(1):181-2 [8392791.001]
  • [Cites] J Pathol. 2006 Apr;208(5):708-13 [16429393.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91 [17692090.001]
  • [Cites] Histopathology. 1997 Mar;30(3):249-55 [9088954.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1750-2 [10749149.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1513-9 [8360934.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [Cites] Pathology. 1979 Jan;11(1):5-26 [431978.001]
  • [Cites] Gynecol Oncol. 1999 Sep;74(3):385-94 [10479498.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):1012-9 [9706982.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):814-24 [10679651.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):707-23 [15897738.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1260-7 [7590702.001]
  • [Cites] Am J Pathol. 2009 May;174(5):1597-601 [19349352.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Histopathology. 1981 Jan;5(1):61-8 [7216177.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1102-8 [10478671.001]
  • [Cites] Oncogene. 1994 Apr;9(4):1163-6 [8134118.001]
  • [Cites] Jpn J Cancer Res. 1998 Oct;89(10 ):985-90 [9849574.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:44-50 [11093061.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1268-74 [7590703.001]
  • [Cites] Gynecol Oncol. 1992 Dec;47(3):298-305 [1473741.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1604-7 [8137266.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12 ):2500-3 [9635567.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2073-81 [18720479.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1519-30 [17122507.001]
  • (PMID = 19859732.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 88
  •  go-up   go-down


79. Klemba A, Kukwa W, Bartnik E, Krawczyk T, Scińska A, Golik P, Czarnecka AM: [Molecular biology of endometrial carcinoma]. Postepy Hig Med Dosw (Online); 2008 Aug 18;62:420-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular biology of endometrial carcinoma].
  • [Transliterated title] Biologia molekularna i diagnostyka raka endometrium.
  • Endometrial carcinoma is among the most frequently diagnosed gynecological malignancies in highly developed countries.
  • The participation of abnormalities of those organelles and mutations of the mitochondrial genome has been defined in some types of cancer and is still under investigation.
  • MtDNA mutations are also found in endometrial adenocarcinoma, although their impact on cell physiology has not been determined so far.
  • A forward genetics approach has been used in a wide spectrum of projects in which cancer tissue samples were collected from subjects with defined diagnoses and metabolic abnormalities and mtDNA mutations were checked.
  • Thanks to this approach, characteristic patterns of mitochondrial disruption have been assigned to specific types of cancer.
  • This review focuses on the molecular characteristics of endometrial adenocarcinoma with special focus on mitochondrial abnormalities.
  • Research on cancer molecular pathology in endometrial adenocarcinoma may lead to the development of specific screening and/or diagnostic markers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18772847.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial
  • [Number-of-references] 44
  •  go-up   go-down


80. Inoue M: [Prognostic factors uterine corpus cancer]. Gan To Kagaku Ryoho; 2006 Dec;33(13):2008-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors uterine corpus cancer].
  • The accumulated clinico-pathological dates and recent molecular biological studies have identified several prognostic factors for endometrial cancers.
  • Molecular markers indicating genetic/molecular events in cancer biology appear to be the 3rd predictors in estimating the prognosis.
  • Finally, treatment of uterine corpus cancer can be directly related to prognosis.
  • [MeSH-major] Lymph Nodes / pathology. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197744.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 36
  •  go-up   go-down


81. Uchida H, Maruyama T, Ono M, Ohta K, Kajitani T, Masuda H, Nagashima T, Arase T, Asada H, Yoshimura Y: Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology; 2007 Feb;148(2):896-902
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin.
  • We have reported previously that treatment with HDACIs, including trichostatin A and suberoylanilide hydroxamic acid (SAHA) or progesterone in combination with estrogen, can induce cytodifferentiation of endometrial adenocarcinoma Ishikawa cells through up-regulation of glycodelin, a progesterone-induced endometrial glycoprotein.
  • Given the reported role of glycodelin in cell motility and the migration-modulating potential of HDACIs, we investigated using wound healing assay and transwell migration assay whether ovarian steroid hormones, trichostatin A, or SAHA affects cell migration in endometrial cancer cell lines, Ishikawa and RL95-2.
  • Our results collectively indicate that glycodelin positively regulates cell motility acting as a mediator of HDACI-enhanced endometrial cell migration, suggesting the involvement of glycodelin in the dynamic endometrial gland morphogenesis during menstrual cycle.
  • Our results raise a possibility that the use of HDACIs in the therapy for glycodelin-inducible endometrial and presumably other gynecological cancers may enhance invasion in cases in which the HDACIs fail to exert differentiation-inducing and/or antiproliferative effects.
  • [MeSH-major] Adenocarcinoma / physiopathology. Cell Movement / drug effects. Endometrial Neoplasms / physiopathology. Enzyme Inhibitors / pharmacology. Glycoproteins / metabolism. Histone Deacetylase Inhibitors. Pregnancy Proteins / metabolism

  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17068141.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Fibronectins; 0 / Glycoproteins; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / PAEP protein, human; 0 / Pregnancy Proteins; 3X2S926L3Z / trichostatin A; 58IFB293JI / vorinostat
  •  go-up   go-down


82. Aida T, Takebayashi Y, Shimizu T, Okamura C, Higasimoto M, Kanzaki A, Nakayama K, Terada K, Sugiyama T, Miyazaki K, Ito K, Takenoshita S, Yaegashi N: Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma. Gynecol Oncol; 2005 Apr;97(1):41-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma.
  • However, the clinical significance of this transporter has not previously been addressed in endometrial carcinoma.
  • Our goal was to investigate if ATP7B is expressed in endometrial carcinoma and whether its expression correlates with prognosis.
  • METHODS: We performed immunohistochemical analysis of ATP7B using a monoclonal antibody against ATP7B in 51 endometrial endometrioid adenocarcinomas.
  • RESULTS: Cytoplasmic staining of tumor cells was observed in 37.3% (19/51 cases) of the analyzed carcinomas and no staining was observed in adjacent non-neoplastic cells.
  • ATP7B positivity in the degree of differentiation of G2 and G3 carcinoma was significantly higher than that of G1 carcinoma (P = 0.019).
  • CONCLUSIONS: These findings suggest that overexpression of ATP7B expression in endometrial carcinoma is correlated with unfavorable clinical outcome in patients treated with cisplatin-based chemotherapy.
  • ATP7B expression could be considered as a prognostic factor in patients with endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenosine Triphosphatases / biosynthesis. Biomarkers, Tumor / biosynthesis. Cation Transport Proteins / biosynthesis. Endometrial Neoplasms / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790435.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Cation Transport Proteins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.3.4 / Wilson disease protein
  •  go-up   go-down


83. Kapali M, Agaram NP, Dabbs D, Kanbour A, White S, Austin RM: Routine endometrial sampling of asymptomatic premenopausal women shedding normal endometrial cells in Papanicolaou tests is not cost effective. Cancer; 2007 Feb 25;111(1):26-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine endometrial sampling of asymptomatic premenopausal women shedding normal endometrial cells in Papanicolaou tests is not cost effective.
  • BACKGROUND: Following The Bethesda System 2001 (TBS 2001) recommendation to report normal endometrial cells (nEMC) in women ages >or=40 years, studies have shown that endometrial (EM) sampling has increased, but detection of significant EM pathology has not increased.
  • In follow-up EM sampling, 6 cases of significant pathology (atypical complex EM hyperplasia or adenocarcinoma) were detected.
  • [MeSH-major] Endometrium / pathology. Papanicolaou Test. Premenopause. Vaginal Smears / economics
  • [MeSH-minor] Adult. Biopsy. Cost-Benefit Analysis. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / economics. Endometrial Neoplasms / pathology. Female. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17262796.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Tokunaga H, Akahira J, Suzuki T, Moriya T, Sasano H, Ito K, Yaegashi N: Ovarian epithelial carcinoma with estrogen-producing stroma. Pathol Int; 2007 May;57(5):285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian epithelial carcinoma with estrogen-producing stroma.
  • Malignant ovarian neoplasms derived from ovarian epithelium that produce estrogen are rare among postmenopausal women.
  • Presented herein is a case of stage Ic(a) endometrioid adenocarcinoma in the right ovary of an 81-year-old woman, who complained of mammary tenderness, pain and atypical genital bleeding.
  • Her serum estradiol (E2) concentration was 83 pg/mL before treatment, and the endometrial thickness measured by transvaginal ultrasonography was 5 cm, much thicker than that expected for a woman in her 80s.
  • Immunohistological data indicated that this epithelial ovarian cancer could produce estradiol by itself, through potential interactions between cancer cells and stromal cells, and that the high level of estradiol in the patient's serum was caused by intratumoral production.
  • This case indicates that in addition to stromal tumors, such as granulosa cell tumors, theca cell tumors, adenofibroma and so on, malignant epithelial tumors with a functioning stroma should also be considered when evaluating ovarian tumors with estrogen production in the elderly.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Estrogens / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493177.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Estrogens; 4TI98Z838E / Estradiol
  •  go-up   go-down


85. McCluggage WG, Connolly LE, McGregor G, Hyland PL, Hall PA: A Strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. Int J Gynecol Pathol; 2005 Oct;24(4):307-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia.
  • Six uterine endometrioid carcinomas, one uterine serous carcinoma (USC) and a proliferative endometrium were stained with antip53 antibody D07 at varying dilutions.
  • The proliferative endometrium exhibited positive staining of >95% of epithelial cells at low dilutions but at high dilutions most epithelial cells were negative.
  • The proportion of positive tumor nuclei in the endometrioid carcinomas varied markedly with antibody concentration.
  • [MeSH-major] Endometrial Neoplasms / chemistry. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adenocarcinoma / chemistry. Antibodies / analysis. Cell Nucleus / chemistry. Female. Humans. Immunohistochemistry / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175073.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


86. Mäenpää JU, Nyberg R, Parkkinen J: Port-site metastasis following laparoscopic hysterectomy and bilateral salpingo-ophorectomy for endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol; 2009 Mar;143(1):61-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Port-site metastasis following laparoscopic hysterectomy and bilateral salpingo-ophorectomy for endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / secondary. Gynecologic Surgical Procedures / adverse effects. Laparoscopy / adverse effects. Pelvic Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136193.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Ireland
  •  go-up   go-down


87. Sireci AN, Crapanzano JP, Mansukhani M, Wright T, Babiac A, Erroll M, Vazquez M, Saqi A: Atypical glandular cells (AGC): ThinPrep Imaging System (TIS), manual screening (MS), and correlation with Hybrid Capture 2 (HC2) HPV DNA testing. Diagn Cytopathol; 2010 Oct;38(10):705-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of the study was to determine if the ThinPrep Imaging System (T1S) improves the positive predictive value (PPV) of atypical glandular cell (AGC) diagnosis for identifying HPV-related squamous and/or glandular lesions over manual screening (MS), and if human papilloma virus (HPV)-DNA testing improves the diagnostic yield.
  • MATERIALS AND METHODS: 85 ThinPrep cervical cytology specimens with a diagnosis of AGC by TIS (n = 51) and MS (n = 34) were retrieved.
  • In the MS group, more cases of glandular pathology were identified, however only three represented adenocarcinoma in-situ (AIS), and the remaining ten were endometrial carcinomas (EMCA).
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Precancerous Conditions / diagnosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Wiley-Liss, Inc.
  • (PMID = 20014311.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


88. Vazmitel M, Pavlovsky M, Kacerovska D, Michal M, Kazakov DV: Pseudoangiomatous stromal hyperplasia in a complex neoplastic lesion involving anogenital mammary-like glands. J Cutan Pathol; 2009 Oct;36(10):1117-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pseudoangiomatous stromal hyperplasia (PASH), a relatively frequent hormonal change associated with different benign and malignant processes in the breast, was only once mentioned in the literature concerning the pathology of AMLG.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adult. Breast Neoplasms / pathology. Endometrial Neoplasms / pathology. Female. Fibroadenoma / pathology. Humans. Hyperplasia. Immunohistochemistry

  • Genetic Alliance. consumer health - Pseudoangiomatous stromal hyperplasia.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 John Wiley & Sons A/S.
  • (PMID = 19508499.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


89. Downs RW Jr, Moffett AM, Ghosh A, Cox DA, Dowsett SA, Harper K: Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass. Osteoporos Int; 2010 Jul;21(7):1215-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial thickness change with arzoxifene was not significantly different from placebo or raloxifene; no cases of endometrial hyperplasia or adenocarcinoma were observed.
  • Within the limitations of this study, the endometrial safety profile of arzoxifene appeared similar to that of raloxifene.
  • [MeSH-minor] Aged. Biomarkers / blood. Bone Density / drug effects. Bone Remodeling / drug effects. Dose-Response Relationship, Drug. Double-Blind Method. Endometrium / drug effects. Endometrium / pathology. Female. Humans. Middle Aged. Raloxifene Hydrochloride / therapeutic use. Selective Estrogen Receptor Modulators / administration & dosage. Selective Estrogen Receptor Modulators / adverse effects. Selective Estrogen Receptor Modulators / therapeutic use. Vasomotor System / drug effects. Vasomotor System / physiopathology

  • Hazardous Substances Data Bank. RALOXIFENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1586-92 [11932287.001]
  • [Cites] J Med Chem. 1997 May 9;40(10):1407-16 [9154963.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Oct;287(1):1-7 [9765314.001]
  • [Cites] JAMA. 1999 Aug 18;282(7):637-45 [10517716.001]
  • [Cites] J Bone Miner Res. 2003 Jun;18(6):1051-6 [12817758.001]
  • [Cites] J Bone Miner Res. 2002 Jan;17(1):1-10 [11771654.001]
  • [Cites] J Bone Miner Res. 2005 Sep;20(9):1514-24 [16059623.001]
  • [Cites] N Engl J Med. 2006 Jul 13;355(2):125-37 [16837676.001]
  • [Cites] JAMA. 2002 Feb 20;287(7):847-57 [11851576.001]
  • [Cites] J Bone Miner Res. 2002 Jan;17(1):11-4 [11771656.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1383-90 [12954577.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3270-5 [12374698.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):2993-3000 [10591680.001]
  • [Cites] Arch Intern Med. 2000 Dec 11-25;160(22):3444-50 [11112238.001]
  • [Cites] JAMA. 1998 May 13;279(18):1445-51 [9600478.001]
  • [Cites] Osteoporos Int. 2001;12(11):922-30 [11808544.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2002-9 [11283133.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8412-5 [11731420.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1007-14 [12637464.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4967-73 [17971595.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5403-17 [15328178.001]
  • (PMID = 19798460.001).
  • [ISSN] 1433-2965
  • [Journal-full-title] Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  • [ISO-abbreviation] Osteoporos Int
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Bone Density Conservation Agents; 0 / LY 353381; 0 / Lipids; 0 / Piperidines; 0 / Selective Estrogen Receptor Modulators; 0 / Thiophenes; 4F86W47BR6 / Raloxifene Hydrochloride
  •  go-up   go-down


90. Leblanc E, Narducci F: [Cancer of the endometrium]. Rev Med Suisse; 2007 Nov 14;3(133):2616-8, 2620-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer of the endometrium].
  • [Transliterated title] Cancers de l'endomètre.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis
  • [MeSH-minor] Brachytherapy. Carcinoma, Endometrioid / diagnosis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Hysterectomy. Laparoscopy. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18078193.001).
  • [ISSN] 1660-9379
  • [Journal-full-title] Revue médicale suisse
  • [ISO-abbreviation] Rev Med Suisse
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


91. Lee B, Sir JJ, Park SW, Kwak CH, Kim SM, Kim SB, Kwak YG, Whang DH, Cho WH, Choi SK: A case of Leclercia adecarboxylata endocarditis in a woman with endometrial cancer. Am J Med Sci; 2009 Feb;337(2):146-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Leclercia adecarboxylata endocarditis in a woman with endometrial cancer.
  • We report an exceptionally rare case of L. adecarboxylata endocarditis complicated by embolization of the kidney and spleen in a 48-year-old woman with endometrial cancer.
  • [MeSH-major] Endocarditis, Bacterial / complications. Endometrial Neoplasms / complications. Enterobacteriaceae / pathogenicity. Enterobacteriaceae Infections / complications
  • [MeSH-minor] Adenocarcinoma / complications. Female. Humans. Infarction / etiology. Kidney / blood supply. Middle Aged. Splenic Infarction / etiology

  • Genetic Alliance. consumer health - Endocarditis.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19214035.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Han JY, Choi DS, Kim C, Joo H, Min CK: Selective gene transfer to endometrial cancer cells by a polymer against matrix metalloproteinase 2 (MMP-2). Cancer Biother Radiopharm; 2008 Apr;23(2):247-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective gene transfer to endometrial cancer cells by a polymer against matrix metalloproteinase 2 (MMP-2).
  • A novel cancer-cell-specific gene delivery vector with high transfection efficiency was designed and tested with an in vitro coculture consisting of the human endometrial adenocarcinoma cell line, HEC-1A cells, and normal endometrial stromal cells.
  • For the cancer-cell targeting, polyethylenimine (PEI), a cationic polymer that can be easily combined with anionic DNA to form a particulate complex, polyplex, being capable of transferring a gene into a variety of cells, was covalently conjugated with antibodies against matrix metalloproteinase 2 (MMP-2), a typical surface-marker protein on cancer cells known for its close correlation with angiogenesis and invasion in many types of cancer, using the heterofunctional cross-linker, n-succinimidyl 3-(2-pyridyldithio)-propionamide.
  • Our results reveal that (1) the PEI-anti-MMP-2 antibody conjugate maintains physical parameters, including sizes and surface charges, which appear to be favorable for gene transfer and (2) when the pEGFP-N3 plasmid complexes of the PEI-anti-MMP-2 antibody conjugate are applied to the coculture consisting of HEC-1A cells and human stromal cells, a high level of green fluorescent protein expression occurs in HEC-1A cells over stromal cells, suggesting a specific gene transfer targeting cancer cells.
  • Therefore, targeting invading cancer cells with the PEI-anti-MMP-2 antibody conjugate could be promising in endometrial cancer treatment, and this gene delivery system deserves further optimization in the context of targeted therapeutic gene delivery.
  • [MeSH-major] Endometrial Neoplasms / enzymology. Endometrial Neoplasms / genetics. Imines / chemistry. Matrix Metalloproteinase 2 / metabolism. Polyethylenes / chemistry. Transgenes / genetics

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454694.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Imines; 0 / Polyethylenes; 0 / poly(ethylene imine); 9007-49-2 / DNA; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


93. Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, Yatabe Y: Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol; 2007 Feb;20(2):208-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, we used the reverse transcription-polymerase chain reaction (RT-PCR) to show that mammaglobin (MGB1) can serve as a differential marker of breast cancer metastasis from primary lung cancer.
  • In this study, we examined MGB1 protein expression in 480 tumors from various organs using immunohistochemical detection and a tissue microarray technique.
  • Of the other cancers examined, including 29 of the head and neck, eight of the thyroid, 106 of the lung, 35 of the gastrointestinal tract, three of the pancreas, 14 of the uterine cervix and 13 of the ovary, none were positive for MGB1 except a proportion of salivary gland tumors (6/11, 55%) and endometrial cancers (3/23, 13%).
  • Among the 238 breast cancers, MGB1 was expressed in 114 (48%), most of which were classified histologically as invasive duct or lobular carcinomas.
  • In terms of practical diagnosis, MGB1 immunohistochemistry can serve as a differential marker of breast cancer metastasis from primary lung cancer for two reasons.
  • Firstly, HER2-positive breast cancer frequently lacks estrogen receptor expression, but MGB1 is expressed in about half of this subtype.
  • Secondly, as primary lung adenocarcinomas may express estrogen receptors, MGB1 expression provides further discrimination of the origin of breast cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. Uteroglobin / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Count. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Japan / epidemiology. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mammaglobin A. Neoplasm Staging. Receptors, Estrogen / metabolism. Survival Rate. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192791.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


94. Shi H, Pan L, Song T: Impact of platinum on the whole mitochondrial genome of ovarian carcinomas both in vivo and in vitro. Int J Gynecol Cancer; 2009 Apr;19(3):423-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of platinum on the whole mitochondrial genome of ovarian carcinomas both in vivo and in vitro.
  • OBJECTIVES: To investigate somatic mitochondrial DNA mutation in primary and recurrent ovarian carcinoma tissues as well as that in drug-resistant cell lines to illuminate the impact of chemotherapeutic drugs on mitochondrial DNA (mtDNA).
  • METHODS: Complete mtDNA genomes of 20 pairs of ovarian carcinomas and their matched normal tissues together with 2 ovarian carcinoma cell lines and their 4 platinum-resistant cell lines were sequenced.
  • RESULTS: A large number of mtDNA new polymorphisms (55) and mutations (18) were identified in 20 ovarian carcinoma samples.
  • CONCLUSIONS: What we found suggested that mtDNA damage could be made by chemotherapeutic drugs but not as much as imagined in ovarian carcinomas.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / secondary. Adult. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / secondary. Drug Resistance, Neoplasm / drug effects. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / genetics. Endometrial Neoplasms / secondary. Female. Humans. In Vitro Techniques. Middle Aged. Mutation / genetics. Polymerase Chain Reaction. Polymorphism, Genetic / genetics. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407571.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / Organoplatinum Compounds
  •  go-up   go-down


95. Giatromanolaki A, Bates GJ, Koukourakis MI, Sivridis E, Gatter KC, Harris AL, Banham AH: The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol; 2008 Aug;110(2):216-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.
  • In this study, we investigated the numbers of FOXP3(+) Tregs in the normal and malignat endometrium and examined potential links with tumor angiogenesis.
  • METHODS: Paraffin-embedded tissues from 79 patients with stage I endometrial adenocarcinoma and 12 samples from normal endometrium were analyzed using immunohistochemistry for the detection of FOXP3(+) lymphocytes.
  • RESULTS: In normal endometrium, FOXP3 was expressed by stroma infiltrating lymphocytes, with a mean number 8 (range 5-11) lymphocytes per x100 optical field.
  • CONCLUSIONS: The correlation between the presence of FOXP3(+) Tregs and high vessel density in endometrial adenocarcinomas suggests a link between immunity, intratumoral angiogenesis and poor prognosis.
  • However, further studies are required as significantly fewer Tregs were detected in the tumor microenvironment compared to normal endometrium.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / immunology. Endometrial Neoplasms / blood supply. Endometrial Neoplasms / immunology. Forkhead Transcription Factors / immunology. Lymphocytes, Tumor-Infiltrating / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Endometrium / immunology. Female. Humans. Immunohistochemistry. Neoplasm Staging. Neovascularization, Pathologic / blood. Neovascularization, Pathologic / immunology. Neovascularization, Pathologic / pathology. Receptors, Estrogen / biosynthesis. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533240.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Receptors, Estrogen
  •  go-up   go-down


96. Sebastianelli A, Renaud MC, Grégoire J, Roy M, Plante M: Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease. J Obstet Gynaecol Can; 2010 Sep;32(9):856-860
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease.
  • OBJECTIVE: To evaluate if a preoperative serum CA 125 level>or=35 kU/L in patients with endometrial cancer correlates with a surgical stage III or IV and poor histopathological prognostic factors.
  • METHODS: We conducted a retrospective cohort study of 254 patients who underwent hysterectomy and full staging for endometrial cancer.
  • Preoperative serum CA 125 was available for each patient as well as complete clinical and histopathological data.
  • A statistically higher number of patients from the stage III or IV group had a serum CA 125 level>or=35 kU/L (58%) compared with the stage I or II group (16%) (OR 7.44; P<0.001).
  • There was no correlation between serum CA 125 level and histological subtype.
  • Patients with stage I or II disease and serum CA 125>or=35 kU/L (46%) had significantly more frequent deep myometrial invasion (>50%) than did those with serum CA 125<35 kU/L (18%) (OR 3.68; P=0.006).
  • CONCLUSION: Assay of the preoperative serum CA 125 level is a very simple test to detect patients with more advanced stage endometrial adenocarcinoma.
  • [MeSH-major] CA-125 Antigen / blood. Carcinoma / blood. Carcinoma / pathology. Endometrial Neoplasms / blood. Endometrial Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21050518.001).
  • [ISSN] 1701-2163
  • [Journal-full-title] Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
  • [ISO-abbreviation] J Obstet Gynaecol Can
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


97. Wadehra M, Mainigi M, Morales SA, Rao RG, Gordon LK, Williams CJ, Braun J: Steroid hormone regulation of EMP2 expression and localization in the endometrium. Reprod Biol Endocrinol; 2008 Apr 09;6:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroid hormone regulation of EMP2 expression and localization in the endometrium.
  • BACKGROUND: The tetraspan protein epithelial membrane protein-2 (EMP2), which mediates surface display of diverse proteins, is required for endometrial competence in blastocyst implantation, and is uniquely correlated with poor survival from endometrial adenocarcinoma tumors.
  • METHODS: Frozen human proliferative and secretory endometrium were collected and analyzed for EMP2 expression using SDS-PAGE/Western blot analysis.
  • The response of EMP2 to progesterone and estradiol was determined using a combination of real-time PCR, SDS-PAGE/Western blot analysis, and confocal immunofluorescence in the human endometrial carcinoma cell line RL95-2.
  • RESULTS: Within normal human endometrium, EMP2 expression is upregulated in the secretory phase relative to the proliferative phase.
  • Similar to results observed in humans, progesterone upregulated endometrial EMP2 expression and induced EMP2 translocation to the plasma membrane.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2006 Oct;147(10):4904-16 [16794013.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):90-8 [16736513.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3890-5 [11389031.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4991-5000 [11600576.001]
  • [Cites] Endocrinology. 2002 Jun;143(6):2119-38 [12021176.001]
  • [Cites] Mol Reprod Dev. 2002 Sep;63(1):47-54 [12211060.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41094-100 [12189152.001]
  • [Cites] Mol Endocrinol. 2002 Dec;16(12):2853-71 [12456805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2963-8 [12601161.001]
  • [Cites] Exp Mol Pathol. 2003 Apr;74(2):106-12 [12710941.001]
  • [Cites] Clin Immunol. 2003 May;107(2):129-36 [12763482.001]
  • [Cites] Recent Prog Horm Res. 2003;58:199-226 [12795420.001]
  • [Cites] Placenta. 2004 Apr;25 Suppl A:S26-31 [15033303.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2073-83 [14978215.001]
  • [Cites] J Soc Gynecol Investig. 1998 Nov-Dec;5(6):334-8 [9824816.001]
  • [Cites] Semin Reprod Med. 2005 Feb;23(1):38-45 [15714388.001]
  • [Cites] Dev Biol. 2005 Nov 15;287(2):336-45 [16216233.001]
  • [Cites] Dev Biol. 2006 Apr 15;292(2):430-41 [16487956.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2323-6 [11344246.001]
  • (PMID = 18400107.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA016042; United States / NICHD NIH HHS / HD / R03 HD048540; United States / NICHD NIH HHS / HD / HD40376; United States / NCI NIH HHS / CA / P30 CA016042; United States / NICHD NIH HHS / HD / T32 HD007305; United States / NCI NIH HHS / CA / T32 CA009120; United States / NICHD NIH HHS / HD / HD48540
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EMP2 protein, human; 0 / Emp2 protein, mouse; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ PMC2329639
  •  go-up   go-down


98. Irvin W, Evans SR, Andersen W, Jazaeri A, Taylor P, Stoler M, Pastore L, Rice L: The utility of HPV DNA triage in the management of cytological AGC. Am J Obstet Gynecol; 2005 Aug;193(2):559-65; discussion 565-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Following institutional review board approval, 28 women presenting with cytological atypical glandular cells underwent repeat thin-prep cytology, Hybrid Capture 2 human papilloma virus DNA testing, colposcopic evaluation, Fisher electrosurgical conization, and endometrial sampling.
  • RESULTS: Sixteen of the 28 study patients had pathologic lesions (11/28 high-grade squamous intraepithelial lesion, 3/28 low-grade squamous intraepithelial lesion, 1/28 adenocarcinoma in situ, 1/28 simple endometrial hyperplasia).
  • Human papilloma virus positivity was not predictive of endometrial pathology; women who were human papilloma virus positive were less likely to have endometrial pathology than were women who were human papilloma virus negative (risk ratio 1.6, 95% confidence interval 0.01-1.7).
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Female. Humans. Middle Aged. Triage


99. Modica I, Soslow RA, Black D, Tornos C, Kauff N, Shia J: Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol; 2007 May;31(5):744-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma.
  • Identification of the microsatellite instability (MSI) phenotype in endometrial carcinoma is important given that such tumors are the most common noncolorectal tumors to occur in hereditary nonpolyposis colorectal cancer syndrome, and may bear prognostic relevance.
  • The objective of this study was to assess the utility of immunohistochemistry (IHC), a simple and fast technique, in detecting MSI in endometrial carcinoma.
  • The study subjects consisted of 90 endometrial carcinoma patients with equal representation of MSI-high (MSI-H) and non-MSI-H tumors.
  • The most common IHC abnormality in MSI tumors was concurrent loss of MLH1/PMS2.
  • In conclusion, our results suggest that IHC is useful in detecting MSI in endometrial carcinoma.
  • Although IHC has a lower sensitivity with more apparent staining inadequacies in detecting MSI in endometrial carcinoma than it does in colorectal carcinoma, its use in endometrial carcinoma may be an important adjunct when screening for hereditary cases.
  • In the future, as prognostic and therapeutic implications of MSI phenotype become better defined, it may be reasonable to perform IHC for mismatch repair proteins in large numbers of endometrial carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Immunoenzyme Techniques. Microsatellite Instability. Microsatellite Repeats / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460459.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


100. Bellone S, Shah HR, McKenney JK, Stone PJ, Santin AD: Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol; 2008 Sep;199(3):e7-e10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
  • Recurrent/metastatic endometrial adenocarcinoma that is not amenable to cure with local or regional therapy and/or chemotherapy represents a discouraging clinical entity for the clinician.
  • We report the case of 58-year-old woman with recurrent endometrial carcinoma that was resistant to chemotherapy that was treated successfully with the aromatase inhibitor anastrozole.
  • [MeSH-major] Adenocarcinoma / drug therapy. Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550023.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down






Advertisement